

Richard Edwin Pratley, M.D.

Personal Data:

Office Address: AdventHealth Translational Research Institute
301 East Princeton Street
Orlando, FL 32804
(407) 303-2519

Home Address: 673 Balmoral Road
Winter Park FL 32789
(407) 622-0275
(407) 883-2060 (mobile)

E-mail: Richard.Pratley.MD@AdventHealth.com

Education:

1975 Eaton Rapids High School, Eaton Rapids, MI 48827

1979 B.S., University of Michigan, Ann Arbor, MI 48109

1983 M.D., Wayne State University, Detroit, MI 48201

Postgraduate Training:

06/1983 – 06/1986 Intern and Resident
Department of Medicine
University of Michigan
Ann Arbor, MI 48109

07/1986 – 06/1987 Fellow
Department of Medicine, Division of Geriatrics
University of Michigan
Ann Arbor, MI 48109

07/1987 – 06/1990 Fellow
Department of Medicine
Division of Gerontology and Geriatric Medicine
Johns Hopkins University
Baltimore, MD 21224

06/1988 – 06/1990 Medical Staff Fellow
Laboratory of Clinical Physiology/Metabolism Section
Gerontology Research Center
National Institute on Aging
Baltimore, MD 21224

Professional Experience:

07/1990 – 06/1993 Assistant Professor (Tenure Track)
Department of Medicine/Division of Gerontology
University of Maryland at Baltimore
Baltimore, MD 21201

07/1990 – 06/1993 Staff Physician
Geriatrics Service/Baltimore Veterans Affairs Medical Center
Baltimore, MD 21201

07/1993 – 10/2000 Investigator
 Clinical Diabetes and Nutrition Section
 National Institute of Diabetes and Digestive and Kidney Diseases
 National Institutes of Health
 Phoenix, AZ 85016

07/1999 – 10/2000 Head
 Diabetes and Metabolism Unit
 Clinical Diabetes and Nutrition Section
 National Institute of Diabetes and Digestive and Kidney Diseases
 National Institutes of Health
 Phoenix, AZ 85016

10/2000 – 04/2004 Senior Clinical Research Physician/Senior Director
 Cardiovascular and Metabolism Business Franchise
 Clinical Research and Development
 Novartis Pharmaceuticals Corporation
 East Hanover, NJ 07936

Medical Director, NAVIGATOR Study
 Global Clinical Program Leader Phase 2-3 Diabetes Project

04/2004 – 04/2011 Professor of Medicine
 University of Vermont College of Medicine
 Burlington, VT 05401

04/2004 – 04/2011 Director
 Diabetes and Metabolism Translational Medicine Unit
 Department of Medicine
 University of Vermont College of Medicine
 Burlington, VT 05401

04/2004 – 04/2011 Attending Physician
 Fletcher Allen Health Care
 Burlington, VT 05401

04/2011 – 10/2013 Professor
 Sanford Burnham Prebys Medical Discovery Institute at Lake Nona
 Orlando, FL 32827

10/2013 – 09/2016 Adjunct Professor
 Sanford Burnham Prebys Medical Discovery Institute at Lake Nona
 Orlando, FL 32827

04/2011 – Present Medical Director
 AdventHealth Diabetes Institute
 Orlando, FL 32804

04/2011 – Present Senior Investigator and Diabetes Program Lead
 AdventHealth Translational Research Institute (TRI)
 Orlando, FL 32804

Certification:

American Board of Internal Medicine
 Diplomate: Internal Medicine #107709, 1986
 Diplomate: Geriatric Medicine #107709, 1992

Licensure:

Florida #: ME110521
 Vermont #: 042-0010757

Honors and Awards:

Honors, Cellular and Molecular Biology, University of Michigan, 1979
 Distinguished Service Award, Wayne State University, 1983
 Henry Christian Award for Excellence in Clinical Research, American Federation for Clinical Research, 1992
 Best paper published in the journal Obesity, 2008
 Samuel E. Crockett, MD Chair in Diabetes Research, Florida Hospital 2012

Professional Affiliations:

American Diabetes Association
 European Association for the Study of Diabetes
 American Association of Clinical Endocrinologists
 The Obesity Society

Other Professional Responsibilities:

1991 – 1993	Established and staffed a CVD risk factor reduction clinic for older veterans
1994 – 2000	Established and staffed a diabetes clinic for older Native Americans
1993 – 1998	NIDDK/PECRB Radiation Safety Committee member
1993 – 2000	NIDDK/PECRB Clinical Research Unit Medical Director
1996 – 2000	NIDDK/NIAMS Institutional Review Board member
1996 – 2000	NIDDK/PECRB EEO Counselor
2004 – 2011	Fletcher Allen Regional Diabetes Center Advisory Board
2005 – 2008	UVM College of Medicine Admissions Committee
2005 – 2008	Fit & Healthy Vermonters Advisory Board, VT State Dept. of Health
2005 – 2008	Medical Practice Sub-Committee, State Dept. of Health Obesity Project
2004 – 2011	UVM Division of Endocrinology Fellows Education Committee
2005 – 2011	Vermont Cancer Center Clinical Research Oversight Committee
2005 – 2011	Department of Medicine Research Committee
2005 – 2011	UVM College of Medicine New Research Initiatives Review Committee
2006 – 2011	UVM Office of Clinical Trials Advisory Committee
2009 – 2011	UVM Clinical and Translational Science Center Executive Committee
2014 – Present	Translational Research Institute, Institute Leadership Committee
2014 – Present	Chair, Translational Research Institute Medical Oversight Committee
2014 – Present	Chair, Translational Research Institute Pharmacy Oversight Committee

Research Interests:

Pathophysiology of type 2 diabetes
 Novel therapeutic approaches for the prevention and treatment of type 2 diabetes
 Novel therapeutic approaches for the prevention and treatment of type 1 diabetes
 Diabetes in older adults
 Obesity, diabetes and Alzheimer's disease

NIH Peer Review Service (last 3 years):

03/2016	NIDDK SBIR Special Emphasis Panel
06/2016	NIDDK SBIR Special Emphasis Panel
07/2016	NIDDK SBIR Special Emphasis Panel
03/2017	NIDDK SBIR Special Emphasis Panel
11/2017	NIDDK SBIR Special Emphasis Panel
03/2018	NIDDK SBIR Special Emphasis Panel

06/2018 NIDDK SBIR Special Emphasis Panel
 11/2018 NIDDK SBIR Special Emphasis Panel
 03/2019 NIDDK SBIR Special Emphasis Panel

Multicenter Clinical Trial Leadership:

2000 – 2003 NAVIGATOR Trial Executive Committee
 2004 – 2009 BARI2D Glycemic Management Committee
 2004 – 2009 BARI2D Sub-studies Committee
 2006 – 2012 Lead Investigator: Alogliptin phase 3 trial program
 2007 – Present IRIS Trial Diabetes Adjudication Committee
 2007 – 2009 Lead Investigator: Vildagliptin Galliant Trial
 2008 – Present GLITZ trial DSMB
 2009 – 2012 Lead investigator: Novo Nordisk Liraglutide Trial
 2009 – 2012 Lead investigator: Roche Taspoglutide Trial
 2009 – 2013 Diabetic Neuropathy Medication DSMB
 2009 – 2014 Lead investigator: GSK Albiglutide Trial
 2009 – Present Chair, LEADER Global Expert Panel
 2009 – Present LEADER Trial Publications Committee
 2013 – Present DEVOTE Trial Steering Committee
 2015 – Present Lead Investigator, SUSTAIN 7 Trial
 2017 – Present Principal Investigator, ACME/NIH ACT1ON Trial
 2017 – Present Principal Investigator, WISDM Trial
 2017 – Present Lead Investigator, PIONEER 4 Trial
 2017 – Present Steering Committee, VERTIS CV Cardiovascular Outcome Trial
 2018 – Present Steering Committee, Amplitude O Cardiovascular Outcome Trial
 2018 – Present Co-Chair, FLOW Renal and Cardiovascular Outcome Trial

Section Editor:

2002 – 2012 Current Diabetes Reports – Metabolic Syndrome

Editorial Board:

2006 – 2012 Diabetes Care
 2009 – 2012 Diabetes Care, Associate Editor
 2008 – 2014 Coronary Artery Disease
 2012 – 2013 Journal of Alzheimer's Disease, Associate Editor
 2012 – 2016 The Review of Diabetic Studies
 2013 – 2015 The Lancet: Diabetes & Endocrinology
 2012 – 2018 Journal of Diabetes and its Complications
 2014 – 2018 Journal of Clinical Endocrinology & Metabolism

Ad Hoc Reviewer:

Coronary Artery Disease
 Diabetes
 Diabetes Care
 Diabetologia
 Endocrinology
 Expert Opinion on Investigational Drugs
 Expert Opinion on Pharmacology
 International Journal of Obesity
 Journal of the American Geriatrics Society
 The Journal of Clinical Endocrinology and Metabolism
 The Lancet
 Obesity

Teaching Experience:

07/1990 – 06/1993	Attending physician: University of Maryland Hospital Supervised medical students, interns, residents in internal medicine
07/1990 – 06/1993	Attending physician: Baltimore VA Geriatrics Clinic Supervised geriatric fellows
07/1990 – 06/1993	Mentored 3 post-doctoral fellows in gerontology
07/1993 – 10/2000	Mentored 3 endocrinology fellows, 4 general internal medicine fellows, 8 pre-medical students (summer), 1 medical student (summer) Clinical supervision - 8 clinical research fellows
04/2004 – 04/2011	Attending physician: Fletcher Allen Hospital Supervised medical students, interns, residents in internal medicine
04/2004 – 04/2011	Didactic Lectures Medical Students (Y1-2) Didactic Lectures Interns and Residents in Internal Medicine Didactic Lectures Endocrinology Fellows and Faculty Didactic Lectures Cardiology, other Post-grad programs

Research Mentor: Endocrine Fellows

Muhammed Hour, MD (Private Practice, Jackson MS)
Susan Trost, MD (Private Practice, Randolph VT)
Vanitha Singaram, MD (Private Practice, Des Moines, IA)
Viral Shah, MD (Private Practice, New Jersey)
Matthew Gilbert, MD (Associate Professor, UVM)

Research Mentor: Undergraduate and post-graduate students:

Julia Cowden, Freeman Fellow
Galadriel Spaulding, PA student
Emily Kolpa, 2nd year medical student
W. Gabe Tharp, MD, PhD 6/14 (Assistant Professor, University of Vermont)
George Kyriazis, PhD (Assistant Professor, Ohio State University)

Thesis Advisor/Committee

Kathleen Woolf (PhD, Arizona State 07/1999)
Xavier Revelo (MS, UVM 05/2008)
Elise Vincelette (Honor's thesis, UVM 05/2008)
Mariya Power (PhD Candidate, Nutrition)
W. Gabe Tharp (PhD, Clinical and Translational Science 06/2014)

National and International Professional Activities:

1995 -- 2000	American Diabetes Association, Arizona Affiliate: Professional Education Committee
1995	Coordinated research poster session at Affiliate sponsored meeting "Diabetes in American Indians and other minorities of the southwest"
1996	Chaired Affiliate/NIH Professional Symposium "Update on the pathogenesis and treatment of non-insulin dependent diabetes mellitus"
1997	Co-chair Affiliate/NIH Professional Symposium "Type 2 diabetes in the elderly: Challenges and opportunities"
1998	Program Committee Affiliate/VA Professional Symposium "Diabetes in the new millennium: Prevention and treatment of complications"
1999	Arizona Science Center: Scientific/medical advisor to: "Pima Indians: A search for balance" an interactive display on diabetes and diabetes research
03/1999-10/2000	American Diabetes Association, Arizona Affiliate President
11/1999-06/2000	American Diabetes Association, Mountain States Region: Regional Board Member
2006	ADA Expert Consensus Committee on the Treatment of Pre-Diabetes
2007	ADA Scientific Sessions – Session Chair

2007 -- 2008	ADA Scientific Sessions Abstract Reviewer
2008	ASH Scientific Sessions Planning Committee
2008	ASH Scientific Sessions Abstract Reviewer
2008	ADA Scientific Sessions – Session Chair
2008 -- 2009	The Obesity Society, Scientific Sessions Planning Committee
2008 -- 2009	The Obesity Society Scientific Sessions Abstract Reviewer
2008 -- 2009	The Obesity Society Scientific Sessions – Session Chair
2008	American Thoracic Society Symposium Discussant
2008	American Diabetes Association Interest Group on Aging and Diabetes
2010	European Association for the Study of Diabetes Annual Meeting –Chair, Oral Presentation
2010	ADA Expert Consensus Committee on the Treatment of Diabetes in the Elderly
2010 -- 2012	American Diabetes Association Scientific Sessions Program Committee
2011 -- 2012	American Diabetes Association, Central & Southwest Florida - Clinical Program Planning Committee
2012 -- 2016	The Obesity Society: Abstract Reviewer
2017	ADA Abstract Reviewer
2018	ADA Abstract Reviewer
2018	ADA/EASD Consensus Guidelines Reviewer

Inventions and Patents:

2004 Use of DPP-4 inhibitors in CHF

Invited Lectures:

- 1997** “Genes and Environment in the Development of NIDDM: Lessons learned from the Pima Indians”, British Nutrition Society Annual Meeting Plenary Lecture, Newcastle, United Kingdom
- 1998** “Leptin and the New Biology of Obesity”, VI Brazilian Congress on Esthetic Medicine
- “Role of Sympathetic Nervous System in Body Weight Regulation and Obesity”, VI Brazilian Congress on Esthetic Medicine
- “Sibutramine and B₃-agonists in the Treatment of Obesity”, VI Brazilian Congress on Esthetic Medicine
- 1999** “Genetics of type 2 diabetes”, GCRC Program Directors Annual Meeting
- 2000** “Importance of Early Insulin Secretion from the Perspective of the Pima Indian Studies”, ADA Satellite Symposium, San Antonio, TX
- “Importance of Early Insulin Secretion in the Pathogenesis of Type 2 Diabetes”, IDF Fairchild Symposium, Paris, France
- 2001** “Role of Adipocytes in the Pathogenesis of Type 2 Diabetes”, Mt Sinai School of Medicine, Diabetes Grand Rounds, New York, NJ
- “The Pathogenesis of Type 2 Diabetes: Insulin Secretion, Fat Cells and Genes”, University of Maryland, Endocrinology Grand Rounds, College Park, MD
- “The Hidden Risks of Postprandial Hyperglycemia”, 2nd Latin American Congress of Internal Medicine, Porlamar, Venezuela
- “Diabetes Prevention: Why and How”, Diabetes 2001 - SMI's 3rd annual diabetes symposium, London, UK
- 2003** "Future Directions: the NAVIGATOR Trial", Serrano-Rios Metabolic Syndrome Symposium, Madrid Spain

"Gene-Environment Interactions in the Pathogenesis of Type 2 Diabetes: Methods and Context", American Diabetes Association Annual Meeting, New Orleans, LA

"DPP4 Inhibition as a Therapeutic Target for the Treatment of Type 2 Diabetes", University of Alabama Department of Nutrition, Birmingham, AL

2004 "Gene-Environment Interactions in the Pathogenesis of Type 2 Diabetes", Endocrine Grand Rounds, University of Pittsburgh. Pittsburgh, PA

2005 "Targeting Gastrointestinal Hormones in Type 2 Diabetes", UTMB Diabetes Program, Galveston, TX

"Obesity and the Development of Type 2 Diabetes and the Metabolic Syndrome", St. Vincent Hospital/U Massachusetts Medica Grand Rounds, Worcester, MA

"Gene-Environment Interactions in the Pathogenesis of Type 2 Diabetes", German Diabetes Association, Berlin, Germany

2006 "Islet Dysfunction: An Underlying Defect in the Pathophysiology of Type 2 Diabetes", Endocrine Society Satellite Symposium, Boston, MA

"New Perspective on Incretin Hormones: Dynamic Relation between Insulin and Glucagon", Strelitz Diabetes Center Grand Rounds, Norfolk, VA

"A Clear Understanding of the Guidelines for Managing T2DM", Antidote Lectures for Primary Care Physicians, Amherst, NY, Dallas, TX, Chicago, IL

2007 "Novel Approaches to the Treatment of Type 2 Diabetes: The Incretin Axis", Joslin Clinic, Boston, MA

"Role of the Adipocyte in the Complications of Obesity: Novel Genes and Therapeutic Targets", Jackson Laboratories, Bar Harbor, ME

"Metabolic Syndrome: A Diabetologist's Perspective", American Heart Association, Rockland, ME

"Incretin Hormone Physiology: Role of GLP-1 and GIP in Glucose Control", ACP Annual Meeting, Satellite Symposium, San Diego, CA

"Update on Incretin Therapies", BARI2D Annual Meeting, Pittsburgh, PA

"DPP-4 Inhibitors in the Treatment of Type 2 Diabetes", American Diabetes Association Annual Meeting, Chicago, IL

2008 "Bariatric Surgery as a Treatment for Metabolic Diseases", United Health Services 5th Annual Weight Management Teaching Day, Binghamton, NY

"Changing the Course of Diabetes: New Insights on the Biologic Effects of Incretin Hormones on Islet Cell Preservation and Glucose Control", ADA Post-Graduate Course Satellite Symposium, San Francisco, CA

"Confronting PPG With Incretins: New Agents with Additional Glucose-Lowering Power and Beneficial Secondary Effects", ACP Annual Meeting Satellite Symposium, Washington, DC

"Leveraging Incretin Hormones for the Treatment of Type 2 Diabetes", Drug Discovery and Development of Innovative Therapeutics Annual Meeting, Boston, MA

"Expanding Treatment Options for Type 2 Diabetes: The Old and the New", American Association of Diabetes Educators Annual Meeting, Washington, DC

"Efficacy and Safety of Alogliptin and Glyburide Combination Therapy in Patients with Type 2 Diabetes", European Association for the Study of Diabetes, Rome, Italy

“Making the Case: Direct and Indirect Benefits of Incretin-Based Therapies”, Endocrine Society Clinical Update, Boston, MA

“Current Status of GLP-1: The Evolving Role of Incretin Therapies in the Treatment of Type 2 Diabetes”, Beijing, China

“DPP-4 Inhibitors and Monotherapy and in Combination Therapy: A Review of the Evidence”, Cardiometabolic Health Conference, Boston, MA

“The New Science of GLP-1: Effects Beyond Glucose Control”, Cardiometabolic Health Conference, Boston, MA

“Incretin Mimetics: Clinical Perspective and Position in the Diabetes Treatment Algorithm”, Cambridge HealthTech Drug Discovery on Target Annual Meeting, Boston, MA

“Current and Investigational DPP-4 Inhibitors”, PriMed Primary Care Update, Baltimore, MD

“Recent Type 2 Diabetes Trials: What are the Implications for Management”, American Society of Hospital Pharmacists Annual Meeting, Orlando, FL

2009 “Diabetes in the Elderly”, University of Texas at Houston Endocrine Grand Rounds, Houston, TX

“Incretin-Based Therapies: Multiple Mechanisms of Action to Address Important Clinical Needs”, American Diabetes Association Annual Post-Graduate Course on Diabetes, New York, NY

“Changing the Course of Diabetes: New Insights on the Biologic Effects of Incretin Hormones on Islet Cell Preservation and Glucose Control”, American Diabetes Association Annual Post-Graduate Course on Diabetes, New York, NY

“Integrating Incretin Based Therapies into Clinical Practice”, PriMed Primary Care Symposium, Fort Lauderdale, FL

“New trials and new treatments: What are the implications for the management of type 2 diabetes”, American Society of Physician Assistants: New York Affiliate Annual Meeting, Lake Placid, NY

“New trials and new treatments: What are the implications for the management of type 2 diabetes”, Vermont Nurse Practitioners Annual Meeting, Stowe, VT

“Evidence for Use of Incretin-Based Therapies”, American College of Clinical Pharmacists Annual Meeting, Orlando, FL

“Role of Incretin-Based Therapies in the Management of Diabetic Hyperglycemia”, PriMed/ADA: Diabetes in Depth, Baltimore, MD, Phoenix, AZ, Portland, OR

“Slowing the Progression of Type 2 Diabetes: Early Intervention in the Primary Care Setting”, PriMed: Primary Care Update, Melville, NY, Miami, FL

“The New Science of GLP-1: Effects Beyond Glucose Control”, American Association of Clinical Endocrinologists Annual Meeting, Houston, TX

“DPP-4 inhibitors: How do their effects differ from those of GLP-1 or Exenatide?”, American Diabetes Association Annual Meeting, New Orleans, LA

“Evidence for use of incretin based therapies”, Endocrine Society Annual Meeting, Washington, DC

“Diabetes in the Elderly”, University of Cincinnati, Endocrine Grand Rounds, Cincinnati, OH

“GLP-1 Therapies”, Diabetes Dialogue, Paris France

“Current and Investigational DPP-4 Inhibitors”, PriMed Primary Care Update, Boston, MA

-
- 2010** “DPP-4 Inhibitors and Other Novel Agents”, American Diabetes Association 57th Annual Postgraduate Course, San Francisco, CA
- “Diabetes in the Older Adult: Target Levels of Glycemia, Lipids and Blood Pressure”, American Diabetes Association 57th Annual Postgraduate Course, San Francisco, CA
- “Head-to-head Incretin Trials”, GLP-1 Global Scientific Expert Meeting, Rome, Italy
- “Incretin Hormones: Insights and Emerging Evidence”, American College of Physicians Annual Meeting, Toronto, Ontario, Canada
- “Integrating DPP-4 Inhibitors Into Current Treatment Paradigms”, American College of Physicians Annual Meeting, Toronto, Ontario, Canada
- “Getting Your Patients to Goal: Oral Antihyperglycemic Combinations and Incretin-based Therapies”, American Diabetes Association Current Concepts in Diabetes, Dearborn, MI
- “Cardiovascular Disease Prevention Guidelines and Application to Clinical Practice”, Medical Grand Rounds, Conway, NH
- “New Drug Regimens for Hyperglycemia in the Elderly”, American Geriatrics Society, Orlando, FL
- “Biology of the Incretin Hormones”, Third Annual Diabetes Symposium, Medical College of Wisconsin, Milwaukee, WI
- “Incretin Hormones: Insights and Emerging Evidence” PriMed Primary Care Update, New York, NY
- “Implementing Incretin-based Therapies”, PriMed Primary Care Update, New York, NY
- “Biology of the Incretin Hormones”, Endocrine Fellows Foundation, Orlando, FL
- “Biology of the Incretin Hormones”, Medical College of Wisconsin Endocrine Grand Rounds, Milwaukee, WI
- “GLP-1 Agonists: An Update on Efficacy and Safety”, American Association of Clinical Endocrinologists. Los Angeles, CA
- “GLP-1 Agonists: An Update on Efficacy and Safety”, University of Minnesota City-Wide Endocrine Grand Rounds. Minneapolis, MN
- “Implementing Incretin-Based Therapies: A Multidisciplinary Approach for Advancing Patient Care for Type 2 Diabetes”, Chair, Rosemont, IL
- “Implementing Incretin-Based Therapies: A Multidisciplinary Approach for Advancing Patient Care for Type 2 Diabetes”, Chair, Baltimore, MD
- “The Science and Safety of Insulin Sensitizers for the Treatment of Type 2 Diabetes”, World Congress of Insulin Resistance and Diabetes. Los Angeles, CA
- “Incretin Therapies for the Treatment of Type 2 Diabetes”, 9th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows. Aventura, FL
- 2011** “Focus on Type 2 Diabetes Comorbidities: Using Incretin-based Therapies in Patients With Renal, Cardiovascular, and Hepatic Insufficiencies”, AACE Annual Meeting, San Diego, CA
- “Pathogenesis of Type 2 Diabetes and Update on New Treatments”, Florida Hospital Medicine Grand Rounds, Celebration, FL

“Management of Diabetes and Comorbidities after Failure of Oral Monotherapies”, Endocrine Society CMES, Boston, MA

“Glycemic Control and Other Considerations in Advanced Kidney Disease”, AACE CME San Diego, CA

“Individualized Medicine in Managing Patients with Type 2 Diabetes Mellitus: A Diabetes Education Station Discussion”, ACCELMED, San Diego, CA

“Glucagon-like Peptide-1 Analogs Update 2011”, Florida Hospital Celebration Health Grand Rounds, Celebration, FL

“Treating Diabetes with Oral Drugs in 2011 – Which is the Correct Paradigm?”, SMA 15th Conference on Hypertension, St. Augustine, FL

“Incretin Hormone Approaches to Treating T2DM: Science and Safety”, Citi-Wide Endocrinology Conference, Translational Research Institute for Metabolism and Diabetes, Winter Park, FL

“Role of Incretin-based Treatments in the Management of Type 2 Diabetes: Clinical Efficacy and Safety”, AACE Educational Meeting, Bethesda, MD

“Incretin Therapy”, Cleveland Clinic Obesity Summit, Cleveland, OH

“Diabetes Trials: What Have We Learned? Where Are we Going?”, Bio-Florida Diabetes Research Panel, Tampa, FL

“Obesity and Diabetes: An Update & Look to the Future”, Halifax Health Annual Diabetes Care Lecture, Daytona Beach, FL

“Incretin Therapies”, Endocrine Fellows 10th Annual Symposium, Los Angeles, CA

“Making Strides with Diabetes Management”, ACP CME, Baltimore, MD

“DPP-4 Inhibitors and GLP-1 Receptor Agonists”, World Diabetes Congress, Dubai, UAE

2012 “Incretin-based Therapies”, Interview Recorded at 2010 World Congress on Insulin Resistance by Audio-Digest Foundation. *DiabetesInsight*. Volume 03, Issue 01 (January 6, 2012). Web. 20 Feb 2012. www.audio-digest.org.

“Pleiotropic Effects of Incretin Therapy”, Takeda 4th β -Cell Advisory Council, Shanghai, China

“DPP-4 Inhibitors and Sufonylurea’s: Replacement or Combination Therapy”, Diabetes for the Internist, American College of Physicians, New Orleans, LA

“Diabetes Update”, American Association of Clinical Endocrinologists 21st Annual Scientific & Clinical Congress, Philadelphia, PA

“Incretin Therapy: Which One, Which Patient, When?”, American Diabetes Association 27th Annual Clinical Conference, Bonita Springs, FL

“Role of GLP-1 and DPP-4 in Type 2 Diabetes: Get to Know the Difference”, Novo Nordisk Corporate Symposium, Philadelphia, PA

“Incretin Therapies”, 11th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows, Dallas, TX

2013 “Insulin Resistance & Glycemic Control: The Role of Incretin Based Therapies”, Physicians’ Academy for Cardiovascular Education Asian Cardio Diabetes Master Class, Hanoi, Vietnam

“Elder Care & Diabetes – Setting Targets, Treating Safely”, American Association of Diabetes Educators Webinar

“Identifying Therapies in Early T2DM - Switching Treatments and the Potential Impact of Nonglycemic Effects”, American Association of Clinical Endocrinologists 22nd Annual Scientific & Clinical Congress, Phoenix, AZ

“Diabetes in the US and FL: Type 2 State of the Union”, ADA Satellite Symposia, Orlando, FL

“Diabetes in the Elderly: A review of the ADA Consensus Statement”, American Diabetes Association 28th Clinical Conference on Diabetes, Orlando, FL

“Treatment of Diabetes in Older Adults with Multiple Comorbidities: The Problem of Polypharmacy”, American Diabetes Association 28th Clinical Conference on Diabetes, Orlando, FL

“Novel Therapeutics”, The Endocrine Society Symposium “The Future of Diabetes Management: New Targets of Diabetes Therapies”, San Francisco, CA

“Examining the New Clinical Data for the Management of Type 2 Diabetes”, Satellite Symposium, 49th European Association of Diabetes Annual Meeting, Barcelona, Spain

“Modern-day Management of T2DM in an Ageing Population”, Satellite Symposium, 49th European Association of Diabetes Annual Meeting, Barcelona, Spain

“How Do GLP-1 Agonists & DPP-4 Inhibitors Differ? Clearing Up the Confusion About Incretin Pathways”, 2013 Cardiometabolic Health Congress, Boston, MA

“Glycemic Management of Type 2 Diabetes”, Endo Bridge 2013, Antalya, Turkey

“Diabetes Case Discussions”, Moderator, Endo Bridge, Antalya, Turkey

“Incretin Therapies”, 12th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows, Dallas, TX

“Use of GLP-1 Receptor Agonists in Special Populations”, International Diabetes Federation Congress, Sydney, Australia

“Type 2 Diabetes: From Pathophysiology to Management”, Satellite Symposium, International Diabetes Federation Congress, Sydney, Australia

2014 “The Evolving Role of Incretin-based Therapies for Diabetes”, Endocrinology and Diabetes Grand Rounds, Gainesville, FL

“When to Initiate Insulin Therapy and How to Minimize the Risk of Hypoglycemia”, American College of Physicians Internal Medicine Conference 2014, Orlando, FL

“Individualized Type 2 Diabetes Management”, Rocky Mountain Metabolic Syndrome Symposium, Aurora, CO

“Tough Diabetes Cases”, Rocky Mountain Metabolic Syndrome Symposium, Aurora, CO

“Role of Antidiabetic Therapies of Glucagon Secretion in Patients with Diabetes”, AACE 23rd Annual Scientific and Clinical Congress CME Symposium, Las Vegas, NV

“Update on Diabetes Treatment”, 2014 National Symposium on the Treatment of Type 2 Diabetes, Guangzhou, Chengdu and Beijing, China

“Individualized Management of Type 2 Diabetes”, 2014 National Symposium on the Treatment of Type 2 Diabetes, Guangzhou, Chengdu and Beijing, China

“GLP-1 Receptor Agonists”, ADA 74th Scientific Sessions, San Francisco, CA

“Initial Treatment of Type 2 Diabetes – The Role of Incretin-base Therapies”, The Best of ADA Brazil 2014, Sao Paulo, Brazil.

“Pathophysiology and predisposing factors of diabetes”, Latin American Metabolic Scientific Exchange, Cancun, Mexico.

“Treatment of diabetes based on pathophysiological knowledge: Recent progress and future options”, Latin American Metabolic Scientific Exchange, Cancun, Mexico.

“The framework for GLP-1 treatment in the current diabetes landscape”, Satellite Symposium, EASD 2014, Vienna, Austria.

“Role of Incretin Therapies and Effects on Glucose Homeostasis”, Satellite Symposium, 2014 Cardiometabolic Health Congress, Boston, MA.

“GLP-1 Receptor Agonists: Similarities and Differences”, Satellite Symposium, 2014 Cardiometabolic Health Congress, Boston, MA.

“Incretin Therapies for the Treatment of Type 2 Diabetes”, 13th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows, Dallas, TX.

2015 “Pharmacologic Modulation of Glucagon and Glucagon Action”, Endocrine Society’s 97th Annual Meeting & Expo, San Diego, CA

“Optimizing Insulin Regimens in T2DM: New Options and Strategies for Effective Glucose Control”, 2015 Cardiometabolic Health Congress Regional Conference Series, Atlanta, GA

“An Asymptomatic 80-year-old woman with a Hemoglobin A1C of 9% on Metformin Therapy”, 2015 Annual Scientific Meeting of the American Geriatrics Society, National Harbor, MD.

“Global Patterns of Cost of Branded & Generic Drugs”, ADA 75th Scientific Sessions, Boston, MA

“Insulin-Based Options: Current Treatment Strategies and the Potential Impact of Emerging Options on Patient Outcomes”, Satellite Symposium, ADA 75th Scientific Sessions, Boston, MA

“Post-prandial Glucose Control: Oral Agent and Non-insulin Injectibles”, Satellite Symposium, ADA 75th Scientific Sessions, Boston, MA

“Alternative Therapies for Type 2 Diabetes When Metformin Fails”, The Best of ADA Spain 2015, Madrid, Spain

“Alternative Therapies for Type 2 Diabetes When Metformin Fails”, The Best of ADA China 2015, Beijing and Shanghai, China

“The Case Elimination Challenge: Clinical Applications for the Use of Antihyperglycemic Therapies in T2DM”, AADE 2015 CE Symposium, New Orleans, LA

“Individualizing Type 2 Diabetes Management: Guidelines for Treatment Intensification”, 2015 Cardiometabolic Health Congress Regional Conference Series, Las Vegas, NV

“Proactive Approaches to Early and Intensive Treatment of T2DM: The Role of Combination Therapy”, 2015 Cardiometabolic Health Congress Regional Conference Series, Las Vegas, NV

“Treatment decisions for our patients: What are the considerations?” Satellite Symposium, EASD 2015, Stockholm, Sweden

“Role of Incretin Therapies and Effects on Glucose Homeostasis”, 14th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows, Dallas, TX

- 2016** “Noninsulin Approaches to Managing Type 2 Diabetes: Best Practices in Combination Therapy”, PriMed Primary Care Updates, Ft. Lauderdale, FL, Houston, TX
- “Type 2 Diabetes: From Pathophysiology to Treatment”, 2nd Edition Meeting with the Expert, Madrid, Barcelona and Sevilla, Spain
- “Diabetes Initiative for Primary Care: Wrestling with an Epidemic”, PriMed Southern Diabetes Initiative - Virtual Expert Roundtable, Newton, MA
- “Type 2 Diabetes – the 21st Century Epidemic: The Role of Alogliptin Monotherapy”, Symposium on Diabetes, Kazan and Moscow, Russia
- “Hospital Management of T2DM: Ensuring Care Coordination across the continuum to Reduce Readmission”, Potomac Center for Medical Education Grand Rounds Series, DeLand, FL, Delray Beach, FL, Kissimmee, FL, Birmingham, AL
- “Current Paradigms in Diabetes Management: An Evidence-Based Approach for Selecting and Sequencing Treatment Strategies”, PriMed Southern Diabetes Initiative: “Overcoming an Epidemic”, Birmingham, AL, Tallahassee, FL, Charleston, WV, Memphis, TN, and Charlotte, NC
- “The Long and Short of GLP-1 Agonists: A Practical Approach to the Complex Nature of T2DM Management”, American College of Physicians’ 2016 Internal Medicine Meeting CME, Washington, DC
- “Differentiating Among DPP-4 Inhibitors: A Focus on Linagliptin”, The Endocrine Society’s Endocrine Society Overview – “Endocrine and Diabetes Regional Dialogue Series”, Live Webcast to India
- “The Evolution of Basal Insulins: One Small Step or a Giant Leap?”, Joslin Diabetes Center Virtual Grand Rounds Series
- “Investigating the different dimensions of DPP-4 inhibitors”, LVI International Congress of the Mexican Society of Nutrition and Endocrinology, Monterrey, Mexico
- “Impact of CVOT results on diabetes management”, GLP-1 Scientific Update Meeting, Tokyo, Japan
- 2017** “Results of Recent Cardiovascular Outcome Trials: What Does the Data Mean to Modern T2DM Management?”, Pri-Med Primary Care Updates: “A Clinician’s Guide to Bridging the Gap Between T2DM and CVD: How to Improve Patient Outcomes”, Ft. Lauderdale, FL, Chicago, IL, and Anaheim, CA
- “Exploring New Therapies in the Individualization of Treatment in Type 2 Diabetes: What Do They Have to Offer?”, National Association of Managed Care Physicians CME online CME Program
- “Novel Therapies for Type 2 Diabetes”, Endocrine Society’s 99th Annual Meeting & Expo: ENDO 2017, Orlando, FL
- “Cardiometabolic Guidelines Update: Finding Consensus Across the Evidence-based Recommendations”, 2nd Annual Cardiometabolic Health Conference, New Orleans, LA
- “Identification and Treatment of Prediabetes to Prevent or Delay the Onset of T2DM”, 2nd Annual Cardiometabolic Health Conference, New Orleans, LA
- “Individualizing Treatment in the Management of Type 2 Diabetes: Novel Therapies for Improved Patient Outcomes”, National Association of Managed Care Physicians 2017 Spring Managed Care Forum, Orlando, FL
- “Integrating Data on Macrovascular and Microvascular Outcomes into Diabetes Management: Evolving Treatment Strategies”, National Association for Continuing Education “Emerging Challenges in Primary Care: Update 2017”, Miami, FL, Atlanta, GA, San Antonio, TX, and Denver, CO

“GLP-1 Receptor Agonists: New Insights and New Strategies for Successful Long-Term Diabetes Management”, National Association for Continuing Education “Emerging Challenges in Primary Care: Update 2017”, Miami, FL, Atlanta, GA, and Denver, CO

“Different Approaches to Obesity in T1DM vs T2DM”, AACE 26th Annual Scientific & Clinical Congress, Austin, TX

“Ultralong-Acting Basal Insulins: Practical Aspects for Managing Your Clinic Patients”, Pri-Med Mini-Expert Perspective “Integrating Newer Basal Insulins in Primary Care: A Case-based Review”, Irving, TX

“New Learnings – Cardiovascular Outcomes”, “New Learnings from the Results of the Liraglutide Effect and Action in Diabetes—Evaluation of Cardiovascular Outcome Results (LEADER) Trial” Symposium, ADA 77th Scientific Sessions, San Diego, CA

“DEVOTE Degludec Cardiovascular Outcomes Trial: Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events” Symposium, ADA 77th Scientific Sessions, San Diego, CA

“Using Injectable Agents Alone and Together to Treat T2DM: Focus on Basal Insulin and GLP-1 Receptor Agonists”, 21st Annual Conference on Hypertension, Diabetes and Lipids, Charleston, SC

“Getting Type 2 Diabetes Patients to Goal – Options After Metformin”, 21st Annual Conference on Hypertension, Diabetes and Lipids, Charleston, SC

“CVD and its Management in T1D”, 1st Annual Heart in Diabetes CME Conference, Philadelphia, PA

“Emerging Non-Insulin Approaches to Better Manage the Complexities of T2DM”, Pri-Med Primary Care Updates, Philadelphia, PA, Rosemont, IL, Atlanta, GA, New York, NY, Tampa, FL

“Beyond Metformin & Sulfonylureas: Emerging Clinical Approaches to Individualized Care”, Pri-Med Southern Diabetes Initiative: “Tackling Diabetes and its Associated Risks: Improving Health Outcomes in the South”, Nashville, TN, Raleigh, SC

“Rethinking the Paradigm for Treating Type 2 Diabetes”, University of Texas Southwestern Medical Center Endocrine Grand Rounds, Dallas, TX

“T2DM AND COMORBID CVD: Applying Clinical Data to Reduce Cardiovascular Risk”, Rockpointe Grand Rounds, Jackson, MS, St. Petersburg, FL

“Implications of Cardiovascular Outcome Trials on Diabetes Treatment Selection”, Cardiometabolic Risk Summit, Dallas, TX

“Aligning Diabetes Practice to High-Quality, Value-Based Care”, PCMH Congress, Orlando, FL

“Role of Incretin Therapies and Effects on Glucose Homeostasis”, 16th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows, Dallas, TX

“Implications of Cardiovascular Outcome Trials with Injectable Agents”, 15th World Congress Insulin Resistance Diabetes & Cardiovascular Disease, Los Angeles, CA

“Key Results”, DEVOTE Symposium at the International Diabetes Federation, Abu Dhabi, UAE

“New Treatments for Type 2 Diabetes: Implications of Cardiovascular Outcome Trials”, FL Chapter American College of Physicians 49th Annual Scientific Meeting, Palm Beach Gardens, FL

2018 “Update on the Guidelines for the Treatment of Type 2 Diabetes”, Beckley VA Hospital, Beckley WV

“Treatment Intensification in T2DM: A Pathophysiologic Approach to Combining GLP-1 Receptor Agonists with Basal Insulin”, Pri-Med Primary Care Updates, Fort Lauderdale, FL, Houston, TX, Anaheim CA, Chicago, IL, Tampa, FL

“Emerging Clinical Approaches to the Effective Management of Diabetes & Associated Risks”, Pri-Med Primary Care Updates, Fort Lauderdale, FL, Anaheim, CA, Rosemont, IL, New York, NY, Baltimore, MD, Boston, MA

“Diabetes Management in Older Adults - The Debate Continues”, American College of Physicians Annual Meeting, New Orleans, LA

“Addressing Postprandial Glycemic Excursions: An Update on the Implications and New Management Strategies for Patients with Type 2 Diabetes”, AACE Annual Meeting, Boston, MA

“The Right Recipe for Achieving PPG Control: To Inhale or Inject?”, Symposium at American Diabetes Association Annual Meeting, Orlando, FL

“Should SGLT2I or GLP-1RAs be the Preferred First Choice Following Metformin?”, Second Annual Heart in Diabetes Meeting, Philadelphia, PA

“Implications of Cardiovascular Outcome Trials on Diabetes Treatment Selection”, Ashland Endocrine Conference, Ashland, OR

“Hypoglycemia is BAD: Advances in Understanding and Implementing Hypoglycemia Risk Reduction Strategies”, Medscape Education Virtual Roundtable

“Advances in Diabetes 2018”, IMEDIC Medical Solutions Webinar for Diabetes Specialists and Senior Endocrinologists across India

“Once-weekly Semaglutide vs once-weekly Dulaglutide”, “Glycaemic control and beyond: shifting the paradigm in diabetes care” Satellite Symposium, EASD 2018, Berlin, Germany

“Ertugliflozin – A Newly Emerging SGLT2 Inhibitor for Patients with Type 2 Diabetes”, “New Insights for Clinician in the Treatment of Patients with Type 2 Diabetes” Satellite Symposium, EASD 2018, Berlin, Germany

“Diabetes in the South: Focus on Prevention”, “Insights on Practical Management of Type 2 Diabetes and Associated Cardiovascular Risk” Southern Medical Association, in collaboration with Clinical Care Options, webinar series

“Individualizing Management of T2DM in the Hospital Setting to Reduce Macro and Microvascular Complications”, Hospital Medicine Summit, Orlando, FL

“Beyond Metformin & Sulfonylureas: Emerging Approaches to Individualizing Care”, Pri-Med Southern Diabetes Initiative, Atlanta, GA

“Implications of Recent Diabetes Cardiovascular Outcome Trials for Clinical Practice”, “Diabetes 2018: My How Things Have Changed!” University of Vermont Diabetes Conference, Burlington, VT

“Incretin Therapies: Effects on Glucose Homeostasis and CVD Risk”, 17th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows, Dallas, TX

“GLP-1 Receptor Agonists: From Bench to Bedside”, Diabetes Dialogue 2018, Madrid, Spain

“Obesity, Metabolic Syndrome and Cardiovascular Disease in T1D”, 16th World Congress Insulin Resistance Diabetes & Cardiovascular Disease, Los Angeles, CA

“Improving the Quality and Cost of Diabetes Care: How Florida Hospital System Discovered and Reduced Hypoglycemia Risks”, American Hospital Association Webinar

“Individualizing Treatment in Type 2 Diabetes to Achieve Glycemic Control and Slow Disease Progression: A Patient-Centered Approach to Care”, Pri-Med Regional Conferences, Phoenix, AZ, Nashville, TN, Los Angeles, CA

- 2019** “Modern Treatment of Type 2 Diabetes: Incorporating the latest evidence and guidelines into practice”, Georgia AACE Annual Meeting, Atlanta, GA
- “Should the Results of Cardiovascular Outcome Trials Change the Way We Treat Type 2 Diabetes?” Endocrine University/Mayo Clinic, Rochester, MN
- “A New Look at Current Clinical Guidelines, CVOT, and Evidence-Based Treatment Options”, “Taking T2DM to Heart: Treating to Decrease CVD” Symposium at American College of Physicians Internal Medicine Meeting, Philadelphia, PA
- “Potential Mechanisms of CV Risk Reductions”, “Cardiovascular Outcome Trials in Diabetes” Symposium at AACE 28th Annual Scientific & Clinical Congress, Los Angeles, CA
- “What are the Diabetes Targets in Elderly Patients”, “Endocrinology in Older Patients: Matching Targets to Outcomes” Symposium at AACE 28th Annual Scientific & Clinical Congress, Los Angeles, CA
- “Combining Oral Diabetes Therapies: How, When, Who, and Why?”, Pri-Med Primary Care Updates, Houston, TX, Nashville, TN, Atlanta, GA, Tampa, FL, Boston, MA
- “Large-Scale Cardiovascular Outcomes Trials with SGLT2 Inhibitors”, “Multidimensional Issues in Type 2 Diabetes: Debates and Discussions Around Cardiovascular and Renal Outcomes” Satellite Symposium at ADA 79th Scientific Sessions, San Francisco, CA
- “Overlap between Autoimmune Diabetes of the Adult and Type 2 Diabetes—Current Knowledge and Clinical Implications”, Chair, Symposium at ADA 79th Scientific Sessions, San Francisco, CA
- “Wireless Innovations for Seniors with Diabetes Mellitus—Primary Results of the WISDM Study”, “Should Advanced Diabetes Technology Be Used in Older Adults” Symposium at ADA 79th Scientific Sessions, San Francisco, CA
- “The Enhanced Role of GLP-1 RA's in Diabetes Management – Which Patients Should We Aim For?”, Medscape Education Virtual Roundtable
- “Diabetes and Heart Disease in Older Patients: Evidence for Targets”, “Role of Ethnicity, Age & Gender on CV Risk in DM” Symposium at Third Annual Heart in Diabetes Meeting, Philadelphia, PA
- “Innovations in GLP-1 Receptor Agonist Therapy: Patient-Centered Strategies to Overcome Barriers and Reduce Cardiometabolic Risk in Type 2 Diabetes Mellitus”, Integrity Continuing Education Miramar Beach, FL
- “Update on Guidelines for Treating Type 2 Diabetes: Addressing CVD and CKD”, AdventHealth Sebring, Sebring, FL
- “The CARES Approach to Patient-Centered Diabetes Management: One Size No Longer Fits All”, Diabetes Care Summit Meeting, Orlando, FL
- “Integrating Comprehensive Cardiovascular Care into Patient Centered Diabetes Management”, Patient-Centered Medical Home (PCMH) Congress, Boston, MA, Dallas, TX
- “Problem-Based Workshop: Pharmacologic Therapy - Complex Clinical Cases”, PriMed Southern Diabetes Initiative, Miami, FL, Charlotte, NC
- “How Do We Overcome Clinical Inertia after Metformin – An Interactive Case” and “The Latest Evidence for Ertugliflozin, a SGLT2 Inhibitor for Patients with Type 2 Diabetes” lecture, Satellite Symposium, EASD 2019, Barcelona, Spain

“Use of new glucose lowering medications in an older population”, International Geriatric Diabetes Workshop, Boston, MA

“Clinical Implications from Cardiovascular Outcomes Trials in Persons with Diabetes: a Focus on PIONEER, REWIND, and CREDENCE”, The Best of ADA India 2019, New Delhi and Kolkata, India

“Why is heart failure still an underappreciated complication of diabetes?”, The Best of ADA India 2019, New Delhi and Kolkata, India

“Management of Renal Disease in Persons with Diabetes”, The Best of ADA Nepal 2019, Kathmandu, Nepal

“The Changing Landscape of Diabetes Therapy and Cardiovascular Risk Reduction”, “Management of Cardiovascular Risk and Type 2 Diabetes in Rural Primary Care” Symposium, Rural Health Clinical Congress 2019, Rye Brook, NY

“Management of the High-Risk Older Patient Based on Contemporary CVOTs”, 17th World Congress Insulin Resistance Diabetes & Cardiovascular Disease, Los Angeles, CA

“Debate: The appropriate medication preventing the next event in a patient with DM & established CVD?”, 17th World Congress Insulin Resistance Diabetes & Cardiovascular Disease, Los Angeles, CA

“Contemporary Role of Older Meds in the Management of Diabetes”, Chair, 17th World Congress Insulin Resistance Diabetes & Cardiovascular Disease, Los Angeles, CA

“Role of Incretin Therapies in the Management of Type 2 Diabetes“, 18th Annual Symposium on Advanced Diabetes Management for Endocrine Fellows, Houston, TX

Peer-Reviewed Articles:

1. Morady F, Nelson SD, Kou WH, **Pratley R**, Schmaltz S, De Buitleir M, Halter JB. Electrophysiologic effects of epinephrine in humans. *J Am Coll Cardiol*. 1988 Jun;11(6):1235-44. PubMed PMID: 2835408.
2. Kaplan MS, **Pratley R**, Hawkins WJ. Silent myocardial ischemia during rehabilitation for cerebrovascular disease. *Arch Phys Med Rehabil*. 1991 Jan;72(1):59-61. PubMed PMID: 1985625.
3. Haythornthwaite JA, **Pratley RE**, Anderson DE. Behavioral stress potentiates the blood pressure effects of a high sodium intake. *Psychosom Med*. 1992 Mar-Apr;54(2):231-9. PubMed PMID: 1565758.
4. Koffler KH, Menkes A, Redmond RA, Whitehead WE, **Pratley RE**, Hurley BF. Strength training accelerates gastrointestinal transit in middle-aged and older men. *Med Sci Sports Exerc*. 1992 Apr;24(4):415-9. PubMed PMID: 1560736.
5. Muller DC, Elahi D, **Pratley RE**, Tobin JD, Andres R. An epidemiological test of the hyperinsulinemia-hypertension hypothesis. *J Clin Endocrinol Metab*. 1993 Mar;76(3):544-8. doi: 10.1210/jcem.76.3.8445009. PubMed PMID: 8445009.
6. Menkes A, Mazel S, Redmond RA, Koffler K, Libanati CR, Gundberg CM, Zizic TM, Hagberg JM, **Pratley RE**, Hurley BF. Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men. *J Appl Physiol* (1985). 1993 May;74(5):2478-84. doi: 10.1152/jappl.1993.74.5.2478. PubMed PMID: 8335581.
7. **Pratley RE**, Coon PJ, Muller DC, Rogus EM, Goldberg AP. The effects of single and sequential insulin infusions on glucose disposal in older men. *Exp Gerontol*. 1993 Jul-Oct;28(4-5):381-91. PubMed PMID: 8224036.
8. **Pratley R**, Nicklas B, Rubin M, Miller J, Smith A, Smith M, Hurley B, Goldberg A. Strength training increases resting metabolic rate and norepinephrine levels in healthy 50- to 65-yr-old men. *J Appl Physiol* (1985). 1994 Jan;76(1):133-7. doi: 10.1152/jappl.1994.76.1.133. PubMed PMID: 8175496.
9. Dengel DR, **Pratley RE**, Hagberg JM, Goldberg AP. Impaired insulin sensitivity and maximal responsiveness in older hypertensive men. *Hypertension*. 1994 Mar;23(3):320-4. PubMed PMID: 8125557.

10. Treuth MS, Ryan AS, **Pratley RE**, Rubin MA, Miller JP, Nicklas BJ, Sorkin J, Harman SM, Goldberg AP, Hurley BF. Effects of strength training on total and regional body composition in older men. *J Appl Physiol* (1985). 1994 Aug;77(2):614-20. doi: 10.1152/jappl.1994.77.2.614. PubMed PMID: 8002507.
11. Miller JP, **Pratley RE**, Goldberg AP, Gordon P, Rubin M, Treuth MS, Ryan AS, Hurley BF. Strength training increases insulin action in healthy 50- to 65-yr-old men. *J Appl Physiol* (1985). 1994 Sep;77(3):1122-7. doi: 10.1152/jappl.1994.77.3.1122. PubMed PMID: 7836113.
12. Ryan AS, Treuth MS, Rubin MA, Miller JP, Nicklas BJ, Landis DM, **Pratley RE**, Libanati CR, Gundberg CM, Hurley BF. Effects of strength training on bone mineral density: hormonal and bone turnover relationships. *J Appl Physiol* (1985). 1994 Oct;77(4):1678-84. doi: 10.1152/jappl.1994.77.4.1678. PubMed PMID: 7836186.
13. **Pratley RE**, Hagberg JM, Rogus EM, Goldberg AP. Enhanced insulin sensitivity and lower waist-to-hip ratio in master athletes. *Am J Physiol*. 1995 Mar;268(3 Pt 1):E484-90. doi: 10.1152/ajpendo.1995.268.3.E484. PubMed PMID: 7900795.
14. **Pratley RE**, Coon PJ, Rogus EM, Goldberg AP. Effects of weight loss on norepinephrine and insulin levels in obese older men. *Metabolism*. 1995 Apr;44(4):438-44. PubMed PMID: 7723665.
15. Hurley BF, Redmond RA, **Pratley RE**, Treuth MS, Rogers MA, Goldberg AP. Effects of strength training on muscle hypertrophy and muscle cell disruption in older men. *Int J Sports Med*. 1995 Aug;16(6):378-84. doi: 10.1055/s-2007-973024. PubMed PMID: 7591389.
16. Ryan AS, **Pratley RE**, Elahi D, Goldberg AP. Resistive training increases fat-free mass and maintains RMR despite weight loss in postmenopausal women. *J Appl Physiol* (1985). 1995 Sep;79(3):818-23. doi: 10.1152/jappl.1995.79.3.818. PubMed PMID: 8567523.
17. **Pratley RE**, Wilson C, Bogardus C. Relation of the white blood cell count to obesity and insulin resistance: effect of race and gender. *Obes Res*. 1995 Nov;3(6):563-71. PubMed PMID: 8653533.
18. Maffei M, Halaas J, Ravussin E, **Pratley RE**, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. *Nat Med*. 1995 Nov;1(11):1155-61. PubMed PMID: 7584987.
19. Gong DW, Bi S, **Pratley RE**, Weintraub BD. Genomic structure and promoter analysis of the human obese gene. *J Biol Chem*. 1996 Feb 23;271(8):3971-4. doi: 10.1074/jbc.271.8.3971. PubMed PMID: 8626726.
20. Dengel DR, **Pratley RE**, Hagberg JM, Rogus EM, Goldberg AP. Distinct effects of aerobic exercise training and weight loss on glucose homeostasis in obese sedentary men. *J Appl Physiol* (1985). 1996 Jul;81(1):318-25. doi: 10.1152/jappl.1996.81.1.318. PubMed PMID: 8828680.
21. Ryan AS, **Pratley RE**, Goldberg AP, Elahi D. Resistive training increases insulin action in postmenopausal women. *J Gerontol A Biol Sci Med Sci*. 1996 Sep;51(5):M199-205. doi: 10.1093/gerona/51a.5.m199. PubMed PMID: 8808989.
22. Nagi DK, Tracy R, **Pratley R**. Relationship of hepatic and peripheral insulin resistance with plasminogen activator inhibitor-1 in Pima Indians. *Metabolism*. 1996 Oct;45(10):1243-7. PubMed PMID: 8843179.
23. Thompson DB, **Pratley R**, Ossowski V. Human primary myoblast cell cultures from non-diabetic insulin resistant subjects retain defects in insulin action. *J Clin Invest*. 1996 Nov 15;98(10):2346-50. doi: 10.1172/JCI119046. PubMed PMID: 8941652; PubMed Central PMCID: PMC507685.
24. **Pratley RE**, Nicolson M, Bogardus C, Ravussin E. Effects of acute hyperinsulinemia on plasma leptin concentrations in insulin-sensitive and insulin-resistant Pima Indians. *J Clin Endocrinol Metab*. 1996 Dec;81(12):4418-21. doi: 10.1210/jcem.81.12.8954052. PubMed PMID: 8954052.
25. Tataranni PA, **Pratley R**, Shuldiner A, Ravussin E. Beta 3-adrenergic receptor gene variant and lipid metabolism in Pima Indians. *Diabetologia*. 1997 Jan;40(1):123-4. PubMed PMID: 9028730.
26. Ravussin E, **Pratley RE**, Maffei M, Wang H, Friedman JM, Bennett PH, Bogardus C. Relatively low plasma leptin concentrations precede weight gain in Pima Indians. *Nat Med*. 1997 Feb;3(2):238-40. PubMed PMID: 9018247.
27. Sakul H, **Pratley R**, Cardon L, Ravussin E, Mott D, Bogardus C. Familiality of physical and metabolic characteristics that predict the development of non-insulin-dependent diabetes mellitus in Pima Indians. *Am J Hum Genet*. 1997 Mar;60(3):651-6. PubMed PMID: 9042926; PubMed Central PMCID: PMC1712495.

28. Tataranni PA, **Pratley R**, Maffei M, Ravussin E. Acute and prolonged administration of glucocorticoids (methylprednisolone) does not affect plasma leptin concentration in humans. *Int J Obes Relat Metab Disord.* 1997 Apr;21(4):327-30. PubMed PMID: 9130032.
29. Paulik MA, Hamacher LL, Yarnall DP, Simmons CJ, Maianu L, **Pratley RE**, Garvey WT, Burns DK, Lenhard JM. Identification of Rad's effector-binding domain, intracellular localization, and analysis of expression in Pima Indians. *J Cell Biochem.* 1997 Jun 15;65(4):527-41. PubMed PMID: 9178102.
30. Snitker S, **Pratley RE**, Nicolson M, Tataranni PA, Ravussin E. Relationship between muscle sympathetic nerve activity and plasma leptin concentration. *Obes Res.* 1997 Jul;5(4):338-40. PubMed PMID: 9285841.
31. Youngren JF, Goldfine ID, **Pratley RE**. Decreased muscle insulin receptor kinase correlates with insulin resistance in normoglycemic Pima Indians. *Am J Physiol.* 1997 Aug;273(2 Pt 1):E276-83. doi: 10.1152/ajpendo.1997.273.2.E276. PubMed PMID: 9277380.
32. **Pratley RE**, Nicolson M, Bogardus C, Ravussin E. Plasma leptin responses to fasting in Pima Indians. *Am J Physiol.* 1997 Sep;273(3 Pt 1):E644-9. doi: 10.1152/ajpendo.1997.273.3.E644. PubMed PMID: 9316457.
33. Wilson CA, Bekele G, Nicolson M, Ravussin E, **Pratley RE**. Relationship of the white blood cell count to body fat: role of leptin. *Br J Haematol.* 1997 Nov;99(2):447-51. doi: 10.1046/j.1365-2141.1997.3873201.x. PubMed PMID: 9375771.
34. Rubin MA, Miller JP, Ryan AS, Treuth MS, Patterson KY, **Pratley RE**, Hurley BF, Veillon C, Moser-Veillon PB, Anderson RA. Acute and chronic resistive exercise increase urinary chromium excretion in men as measured with an enriched chromium stable isotope. *J Nutr.* 1998 Jan;128(1):73-8. doi: 10.1093/jn/128.1.73. PubMed PMID: 9430605.
35. Norman RA, Tataranni PA, **Pratley R**, Thompson DB, Hanson RL, Prochazka M, Baier L, Ehm MG, Sakul H, Foroud T, Garvey WT, Burns D, Knowler WC, Bennett PH, Bogardus C, Ravussin E. Autosomal genomic scan for loci linked to obesity and energy metabolism in Pima Indians. *Am J Hum Genet.* 1998 Mar;62(3):659-68. doi: 10.1086/301758. PubMed PMID: 9497255; PubMed Central PMCID: PMC1376952.
36. **Pratley RE**, Thompson DB, Prochazka M, Baier L, Mott D, Ravussin E, Sakul H, Ehm MG, Burns DK, Foroud T, Garvey WT, Hanson RL, Knowler WC, Bennett PH, Bogardus C. An autosomal genomic scan for loci linked to prediabetic phenotypes in Pima Indians. *J Clin Invest.* 1998 Apr 15;101(8):1757-64. doi: 10.1172/JCI1850. PubMed PMID: 9541507; PubMed Central PMCID: PMC508758.
37. **Pratley RE**. Gene-environment interactions in the pathogenesis of type 2 diabetes mellitus: lessons learned from the Pima Indians. *Proc Nutr Soc.* 1998 May;57(2):175-81. Review. PubMed PMID: 9656318.
38. Mott DM, **Pratley RE**, Bogardus C. Postabsorptive respiratory quotient and insulin-stimulated glucose storage rate in nondiabetic pima indians are related To glycogen synthase fractional activity in cultured myoblasts. *J Clin Invest.* 1998 May 15;101(10):2251-6. doi: 10.1172/JCI1778. PubMed PMID: 9593781; PubMed Central PMCID: PMC508813.
39. Wilson C, Nelson R, Nicolson M, **Pratley R**. Plasma leptin concentrations: no difference between diabetic Pima Indians with and without nephropathy. *Diabetologia.* 1998 Jul;41(7):861-2. PubMed PMID: 9686932.
40. Baier LJ, Dobberfuhl AM, **Pratley RE**, Hanson RL, Bogardus C. Variations in the vitamin D-binding protein (Gc locus) are associated with oral glucose tolerance in nondiabetic Pima Indians. *J Clin Endocrinol Metab.* 1998 Aug;83(8):2993-6. doi: 10.1210/jcem.83.8.5043. PubMed PMID: 9709981.
41. Walder K, Norman RA, Hanson RL, Schrauwen P, Neverova M, Jenkinson CP, Easlick J, Warden CH, Pecqueur C, Raimbault S, Ricquier D, Silver MH, Shuldiner AR, Solanes G, Lowell BB, Chung WK, Leibel RL, **Pratley R**, Ravussin E. Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima indians. *Hum Mol Genet.* 1998 Sep;7(9):1431-5. doi: 10.1093/hmg/7.9.1431. PubMed PMID: 9700198.
42. Dengel DR, Hagberg JM, **Pratley RE**, Rogus EM, Goldberg AP. Improvements in blood pressure, glucose metabolism, and lipoprotein lipids after aerobic exercise plus weight loss in obese, hypertensive middle-aged men. *Metabolism.* 1998 Sep;47(9):1075-82. PubMed PMID: 9751236.
43. Monroe MB, Tataranni PA, **Pratley R**, Manore MM, Skinner JS, Ravussin E. Lower daily energy expenditure as measured by a respiratory chamber in subjects with spinal cord injury compared with control subjects. *Am J Clin Nutr.* 1998 Dec;68(6):1223-7. doi: 10.1093/ajcn/68.6.1223. PubMed PMID: 9846850.

44. Dengel DR, Galecki AT, Hagberg JM, **Pratley RE**. The independent and combined effects of weight loss and aerobic exercise on blood pressure and oral glucose tolerance in older men. *Am J Hypertens*. 1998 Dec;11(12):1405-12. doi: 10.1016/s0895-7061(98)00185-x. PubMed PMID: 9880120.
45. Schrauwen P, Xia J, Bogardus C, **Pratley RE**, Ravussin E. Skeletal muscle uncoupling protein 3 expression is a determinant of energy expenditure in Pima Indians. *Diabetes*. 1999 Jan;48(1):146-9. doi: 10.2337/diabetes.48.1.146. PubMed PMID: 9892236.
46. Gautier JF, Milner MR, Elam E, Chen K, Ravussin E, **Pratley RE**. Visceral adipose tissue is not increased in Pima Indians compared with equally obese Caucasians and is not related to insulin action or secretion. *Diabetologia*. 1999 Jan;42(1):28-34. doi: 10.1007/s001250051108. PubMed PMID: 10027574.
47. Tataranni PA, Gautier JF, Chen K, Uecker A, Bandy D, Salbe AD, **Pratley RE**, Lawson M, Reiman EM, Ravussin E. Neuroanatomical correlates of hunger and satiation in humans using positron emission tomography. *Proc Natl Acad Sci U S A*. 1999 Apr 13;96(8):4569-74. doi: 10.1073/pnas.96.8.4569. PubMed PMID: 10200303; PubMed Central PMCID: PMC16373.
48. Youngren JF, Goldfine ID, **Pratley RE**. Insulin receptor autophosphorylation in cultured myoblasts correlates to glucose disposal in Pima Indians. *Am J Physiol*. 1999 May;276(5):E990-4. doi: 10.1152/ajpendo.1999.276.5.E990. PubMed PMID: 10329994.
49. Silver K, Walston J, Yang Y, **Pratley R**, Ravussin E, Raben N, Shuldiner AR. Molecular scanning of the beta-3-adrenergic receptor gene in Pima Indians and Caucasians. *Diabetes Metab Res Rev*. 1999 May-Jun;15(3):175-80. PubMed PMID: 10441039.
50. Weyer C, Bogardus C, **Pratley RE**. Metabolic factors contributing to increased resting metabolic rate and decreased insulin-induced thermogenesis during the development of type 2 diabetes. *Diabetes*. 1999 Aug;48(8):1607-14. doi: 10.2337/diabetes.48.8.1607. PubMed PMID: 10426380.
51. Weyer C, Bogardus C, Mott DM, **Pratley RE**. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest*. 1999 Sep;104(6):787-94. doi: 10.1172/JCI7231. PubMed PMID: 10491414; PubMed Central PMCID: PMC408438.
52. Weyer C, **Pratley RE**. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. *Obes Res*. 1999 Sep;7(5):444-52. PubMed PMID: 10509601.
53. Weyer C, Bogardus C, **Pratley RE**. Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. *Diabetes*. 1999 Nov;48(11):2197-203. doi: 10.2337/diabetes.48.11.2197. PubMed PMID: 10535454.
54. Gautier JF, Chen K, Uecker A, Bandy D, Frost J, Salbe AD, **Pratley RE**, Lawson M, Ravussin E, Reiman EM, Tataranni PA. Regions of the human brain affected during a liquid-meal taste perception in the fasting state: a positron emission tomography study. *Am J Clin Nutr*. 1999 Nov;70(5):806-10. doi: 10.1093/ajcn/70.5.806. PubMed PMID: 10539739.
55. **Pratley RE**, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. *Ann Neurol*. 2000 Jan;47(1):64-70. PubMed PMID: 10632102.
56. Hanson RL, **Pratley RE**, Bogardus C, Narayan KM, Roumain JM, Imperatore G, Fagot-Campagna A, Pettitt DJ, Bennett PH, Knowler WC. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. *Am J Epidemiol*. 2000 Jan 15;151(2):190-8. doi: 10.1093/oxfordjournals.aje.a010187. PubMed PMID: 10645822.
57. Weyer C, Hanson K, Bogardus C, **Pratley RE**. Long-term changes in insulin action and insulin secretion associated with gain, loss, regain and maintenance of body weight. *Diabetologia*. 2000 Jan;43(1):36-46. doi: 10.1007/s001250050005. PubMed PMID: 10663214.
58. Taylor-Tolbert NS, Dengel DR, Brown MD, McCole SD, **Pratley RE**, Ferrell RE, Hagberg JM. Ambulatory blood pressure after acute exercise in older men with essential hypertension. *Am J Hypertens*. 2000 Jan;13(1 Pt 1):44-51. doi: 10.1016/s0895-7061(99)00141-7. PubMed PMID: 10678270.
59. Ryan AS, **Pratley RE**, Elahi D, Goldberg AP. Changes in plasma leptin and insulin action with resistive training in postmenopausal women. *Int J Obes Relat Metab Disord*. 2000 Jan;24(1):27-32. PubMed PMID: 10702747.
60. Shuldiner AR, Nguyen W, Kao WH, Beamer BA, Andersen RE, **Pratley R**, Brancati FL. Pro115Gln peroxisome proliferator-activated receptor-gamma and obesity. *Diabetes Care*. 2000 Jan;23(1):126-7. doi: 10.2337/diacare.23.1.126a. PubMed PMID: 10857984.

61. Weyer C, **Pratley RE**, Salbe AD, Bogardus C, Ravussin E, Tataranni PA. Energy expenditure, fat oxidation, and body weight regulation: a study of metabolic adaptation to long-term weight change. *J Clin Endocrinol Metab.* 2000 Mar;85(3):1087-94. doi: 10.1210/jcem.85.3.6447. PubMed PMID: 10720044.
62. **Pratley RE**, Caviness J. Weight loss in Huntington's disease (reply to letter). *Ann Neurol.* 2000 March; 48(1):130-131.
63. **Pratley RE**. A shocking case of diabetic neuropathy. *Lancet.* 2000 Apr 29;355(9214):1560. doi: 10.1016/S0140-6736(05)74618-3. PubMed PMID: 10801209.
64. **Pratley RE**, Ren K, Milner MR, Sell SM. Insulin increases leptin mRNA expression in abdominal subcutaneous adipose tissue in humans. *Mol Genet Metab.* 2000 May;70(1):19-26. doi: 10.1006/mgme.2000.2995. PubMed PMID: 10833328.
65. Gautier JF, Chen K, Salbe AD, Bandy D, **Pratley RE**, Heiman M, Ravussin E, Reiman EM, Tataranni PA. Differential brain responses to satiation in obese and lean men. *Diabetes.* 2000 May;49(5):838-46. doi: 10.2337/diabetes.49.5.838. PubMed PMID: 10905495.
66. Weyer C, Tataranni PA, **Pratley RE**. Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration. *Diabetes Care.* 2000 Jun;23(6):779-85. doi: 10.2337/diacare.23.6.779. PubMed PMID: 10840996.
67. **Pratley RE**, Hagberg JM, Dengel DR, Rogus EM, Muller DC, Goldberg AP. Aerobic exercise training-induced reductions in abdominal fat and glucose-stimulated insulin responses in middle-aged and older men. *J Am Geriatr Soc.* 2000 Sep;48(9):1055-61. PubMed PMID: 10983904.
68. Mott DM, Hoyt C, Caspari R, Stone K, **Pratley R**, Bogardus C. Palmitate oxidation rate and action on glycogen synthase in myoblasts from insulin-resistant subjects. *Am J Physiol Endocrinol Metab.* 2000 Sep;279(3):E561-9. doi: 10.1152/ajpendo.2000.279.3.E561. PubMed PMID: 10950823.
69. Baier LJ, Permana PA, Yang X, **Pratley RE**, Hanson RL, Shen GQ, Mott D, Knowler WC, Cox NJ, Horikawa Y, Oda N, Bell GI, Bogardus C. A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. *J Clin Invest.* 2000 Oct;106(7):R69-73. doi: 10.1172/JCI10665. PubMed PMID: 11018080; PubMed Central PMCID: PMC387246.
70. Weyer C, **Pratley RE**, Snitker S, Spraul M, Ravussin E, Tataranni PA. Ethnic differences in insulinemia and sympathetic tone as links between obesity and blood pressure. *Hypertension.* 2000 Oct;36(4):531-7. PubMed PMID: 11040231.
71. Weyer C, **Pratley RE**, Lindsay RS, Tataranni PA. Relationship between birth weight and body composition, energy metabolism, and sympathetic nervous system activity later in life. *Obes Res.* 2000 Nov;8(8):559-65. doi: 10.1038/oby.2000.72. PubMed PMID: 11156431.
72. Weyer C, Hanson RL, Tataranni PA, Bogardus C, **Pratley RE**. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. *Diabetes.* 2000 Dec;49(12):2094-101. doi: 10.2337/diabetes.49.12.2094. PubMed PMID: 11118012.
73. **Pratley RE**, Baier L, Pan DA, Salbe AD, Storlien L, Ravussin E, Bogardus C. Effects of an Ala54Thr polymorphism in the intestinal fatty acid-binding protein on responses to dietary fat in humans. *J Lipid Res.* 2000 Dec;41(12):2002-8. PubMed PMID: 11108733.
74. Weyer C, Foley JE, Bogardus C, Tataranni PA, **Pratley RE**. Enlarged subcutaneous abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. *Diabetologia.* 2000 Dec;43(12):1498-506. doi: 10.1007/s001250051560. PubMed PMID: 11151758.
75. Weyer C, Tataranni PA, Bogardus C, **Pratley RE**. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. *Diabetes Care.* 2001 Jan;24(1):89-94. doi: 10.2337/diacare.24.1.89. PubMed PMID: 11194248.
76. Weyer C, Salbe AD, Lindsay RS, **Pratley RE**, Bogardus C, Tataranni PA. Exaggerated pancreatic polypeptide secretion in Pima Indians: can an increased parasympathetic drive to the pancreas contribute to hyperinsulinemia, obesity, and diabetes in humans?. *Metabolism.* 2001 Feb;50(2):223-30. doi: 10.1053/meta.2001.20170. PubMed PMID: 11229433.
77. Weyer C, Wolford JK, Hanson RL, Foley JE, Tataranni PA, Bogardus C, **Pratley RE**. Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21--q23 and is associated with a common polymorphism in LMNA in Pima Indians. *Mol Genet Metab.* 2001 Mar;72(3):231-8. doi: 10.1006/mgme.2001.3147. PubMed PMID: 11243729.

78. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, **Pratley RE**, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. *J Clin Endocrinol Metab.* 2001 May;86(5):1930-5. doi: 10.1210/jcem.86.5.7463. PubMed PMID: 11344187.
79. Yang X, **Pratley RE**, Baier LJ, Horikawa Y, Bell GI, Bogardus C, Permana PA. Reduced skeletal muscle calpain-10 transcript level is due to a cumulative decrease in major isoforms. *Mol Genet Metab.* 2001 May;73(1):111-3. doi: 10.1006/mgme.2001.3171. PubMed PMID: 11350192.
80. Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, **Pratley RE**. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. *Obes Res.* 2001 Jul;9(7):414-7. doi: 10.1038/oby.2001.54. PubMed PMID: 11445664.
81. Gautier JF, Wilson C, Weyer C, Mott D, Knowler WC, Cavaghan M, Polonsky KS, Bogardus C, **Pratley RE**. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. *Diabetes.* 2001 Aug;50(8):1828-33. doi: 10.2337/diabetes.50.8.1828. PubMed PMID: 11473045.
82. **Pratley RE**, Weyer C. The role of impaired early insulin secretion in the pathogenesis of Type II diabetes mellitus. *Diabetologia.* 2001 Aug;44(8):929-45. doi: 10.1007/s001250100580. Review. PubMed PMID: 11484070.
83. **Pratley RE**, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. *Curr Pharm Des.* 2001 Sep;7(14):1375-97. Review. PubMed PMID: 11472274.
84. Evidente VG, Caviness JN, Adler CH, Gwinn-Hardy KA, **Pratley RE**. Serum leptin concentrations and satiety in Parkinson's disease patients with and without weight loss. *Mov Disord.* 2001 Sep;16(5):924-7. PubMed PMID: 11746624.
85. Gautier JF, Del Parigi A, Chen K, Salbe AD, Bandy D, **Pratley RE**, Ravussin E, Reiman EM, Tataranni PA. Effect of satiation on brain activity in obese and lean women. *Obes Res.* 2001 Nov;9(11):676-84. doi: 10.1038/oby.2001.92. PubMed PMID: 11707534.
86. Vozarova B, Weyer C, Lindsay RS, **Pratley RE**, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes.* 2002 Feb;51(2):455-61. doi: 10.2337/diabetes.51.2.455. PubMed PMID: 11812755.
87. **Pratley RE**. The quality of fat in the diet and its impact on insulin sensitivity. *Curr Diab Rep.* 2002 Feb;2(1):69-70. PubMed PMID: 15279020.
88. Weyer C, Yudkin JS, Stehouwer CD, Schalkwijk CG, **Pratley RE**, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. *Atherosclerosis.* 2002 Mar;161(1):233-42. PubMed PMID: 11882337.
89. Weyer C, **Pratley RE**, Tataranni PA. Role of insulin resistance and insulin secretory dysfunction in the pathogenesis of type 2 diabetes mellitus: Lessons from cross-sectional, prospective and longitudinal studies in the Pima Indians. *Curr Opin Endocrinol Diabetes Obes.* 2002 April; 9(2):130-8.
90. Yang X, **Pratley RE**, Tokraks S, Tataranni PA, Permana PA. UCP5/BMCP1 transcript isoforms in human skeletal muscle: relationship of the short-insert isoform with lipid oxidation and resting metabolic rates. *Mol Genet Metab.* 2002 Apr;75(4):369-73. doi: 10.1016/S1096-7192(02)00008-2. PubMed PMID: 12051969.
91. Stefan N, Vozarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, Youngren JF, Havel PJ, **Pratley RE**, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. *Diabetes.* 2002 Jun;51(6):1884-8. doi: 10.2337/diabetes.51.6.1884. PubMed PMID: 12031977.
92. Vozarova B, Stefan N, Lindsay RS, Saremi A, **Pratley RE**, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes.* 2002 Jun;51(6):1889-95. doi: 10.2337/diabetes.51.6.1889. PubMed PMID: 12031978.
93. Del Parigi A, Chen K, Gautier JF, Salbe AD, **Pratley RE**, Ravussin E, Reiman EM, Tataranni PA. Sex differences in the human brain's response to hunger and satiation. *Am J Clin Nutr.* 2002 Jun;75(6):1017-22. doi: 10.1093/ajcn/75.6.1017. PubMed PMID: 12036808.
94. **Pratley RE**, Weyer C. Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion. *Curr Diab Rep.* 2002 Jun;2(3):242-8. Review. PubMed PMID: 12643180.

95. Yang X, **Pratley RE**, Tokraks S, Bogardus C, Permana PA. Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. *Diabetologia*. 2002 Nov;45(11):1584-93. doi: 10.1007/s00125-002-0905-7. Epub 2002 Aug 23. PubMed PMID: 12436343.
96. **Pratley RE**. Effects of improving insulin sensitivity on nontraditional cardiovascular risk factors in patients with type 2 diabetes. *Curr Diab Rep*. 2003 Feb;3(1):63-4. PubMed PMID: 12685440.
97. Sobngwi E, Boudou P, Mauvais-Jarvis F, Leblanc H, Velho G, Vexiau P, Porcher R, Hadjadj S, **Pratley R**, Tataranni PA, Calvo F, Gautier JF. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. *Lancet*. 2003 May 31;361(9372):1861-5. doi: 10.1016/S0140-6736(03)13505-2. PubMed PMID: 12788573.
98. Lee YH, Tokraks S, **Pratley RE**, Bogardus C, Permana PA. Identification of differentially expressed genes in skeletal muscle of non-diabetic insulin-resistant and insulin-sensitive Pima Indians by differential display PCR. *Diabetologia*. 2003 Nov;46(11):1567-75. doi: 10.1007/s00125-003-1226-1. Epub 2003 Oct 24. PubMed PMID: 14576983.
99. Salbe AD, DelParigi A, **Pratley RE**, Drewnowski A, Tataranni PA. Taste preferences and body weight changes in an obesity-prone population. *Am J Clin Nutr*. 2004 Mar;79(3):372-8. doi: 10.1093/ajcn/79.3.372. PubMed PMID: 14985209.
100. Stefan N, Weyer C, Levy-Marchal C, Stumvoll M, Knowler WC, Tataranni PA, Bogardus C, **Pratley RE**. Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight. *Metabolism*. 2004 Jul;53(7):904-11. PubMed PMID: 15254885.
101. Stefan N, Stumvoll M, Weyer C, Bogardus C, Tataranni PA, **Pratley RE**. Exaggerated insulin secretion in Pima Indians and African-Americans but higher insulin resistance in Pima Indians compared to African-Americans and Caucasians. *Diabet Med*. 2004 Oct;21(10):1090-5. doi: 10.1111/j.1464-5491.2004.01290.x. PubMed PMID: 15384955.
102. **Pratley RE**, Salsali A. Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus. *Sci Med*. 2005; 10(1):13-15.
103. Hourii M, **Pratley RE**. Rimonabant: A novel treatment for obesity and the metabolic syndrome. *Curr Diab Rep*. 2005 January; 5(1):43-4.
104. Lee YH, **Pratley RE**. The evolving role of inflammation in obesity and the metabolic syndrome. *Curr Diab Rep*. 2005 Feb;5(1):70-5. Review. PubMed PMID: 15663921.
105. Mari A, Gastaldelli A, Foley JE, **Pratley RE**, Ferrannini E. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide. *Diabetes Care*. 2005 May;28(5):1132-8. doi: 10.2337/diacare.28.5.1132. PubMed PMID: 15855578.
106. Trost S, **Pratley R**, Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. *Curr Diab Rep*. 2006 Feb;6(1):47-54. Review. PubMed PMID: 16522281.
107. **Pratley RE**. The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes. *Curr Diab Rep*. 2006 Feb;6(1):45-6. PubMed PMID: 16522280.
108. **Pratley RE**, Jauffret-Kamel S, Galbreath E, Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. *Horm Metab Res*. 2006 Jun;38(6):423-8. doi: 10.1055/s-2006-944546. PubMed PMID: 16823726.
109. **Pratley RE**, Salsali A, Matfin G. Inhibition of dipeptidyl peptidase-4 with vildagliptin: a potential new treatment for type 2 diabetes. *Brit Jour of Diab and Vasc Dis*. 2006 July; 6(4):150-6.
110. Sobel BE, Schneider DJ, Lee YH, **Pratley RE**. Insulin resistance increases PAI-1 in the heart. *Biochem Biophys Res Commun*. 2006 Jul 21;346(1):102-7. doi: 10.1016/j.bbrc.2006.05.078. Epub 2006 May 22. PubMed PMID: 16750510.
111. Sobel BE, Lee YH, **Pratley RE**, Schneider DJ. Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age. *Life Sci*. 2006 Sep 20;79(17):1600-5. doi: 10.1016/j.lfs.2006.05.011. Epub 2006 May 19. PubMed PMID: 16750223.
112. Zinman B, **Pratley R**, Ratner R. Emerging strategies for the management of glycemic control: The role of incretin enhancers – Questions and answers. *Endo and Metab Clinics of North Am*. 2006 December; 35(Suppl 1):17-19.
113. **Pratley R**. Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. *Endocrinol Metab Clin North Am*. 2006 Dec;35 Suppl 1:6-11; discussion 17-19. Review. PubMed PMID: 17424674.

114. **Pratley RE.** Long-term glycemic control through preserved beta-cell function. *Curr Med Res Opin.* 2007; 23(4):904.
115. Lee YH, **Pratley RE.** Abdominal obesity and cardiovascular disease risk: the emerging role of the adipocyte. *J Cardiopulm Rehabil Prev.* 2007 Jan-Feb;27(1):2-10. Review. PubMed PMID: 17474638.
116. Shah V, **Pratley RE.** The DREAM Trial: using ramipril and rosiglitazone to prevent diabetes. *Curr Diab Rep.* 2007 Feb;7(1):53-5. PubMed PMID: 17254518.
117. **Pratley RE.** Metabolic syndrome: why the controversy? *Curr Diab Rep.* 2007 Feb;7(1):56-9. Review. PubMed PMID: 17348123.
118. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, **Pratley R,** Zinman B. Impaired fasting glucose and impaired glucose tolerance: implications for care. *Diabetes Care.* 2007 Mar;30(3):753-9. doi: 10.2337/dc07-9920. Review. PubMed PMID: 17327355.
119. **Pratley RE,** Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. *Curr Med Res Opin.* 2007 Apr;23(4):919-31. doi: 10.1185/030079906X162746. Review. PubMed PMID: 17407649.
120. **Pratley RE,** Matfin G. Pre-diabetes: Clinical relevance and therapeutic approach. *Brit Jour of Diab and Vasc Dis.* 2007 May; 7(3):120-9.
121. Salsali A, **Pratley RE.** Does addition of sitagliptin to metformin monotherapy improve glycemic control in patients with type 2 diabetes mellitus?. *Nat Clin Pract Endocrinol Metab.* 2007 Jun;3(6):450-1. doi: 10.1038/ncpendmet0512. Epub 2007 Apr 24. PubMed PMID: 17457306.
122. Rowen M, Schneider DJ, **Pratley RE,** Sobel BE. On rendering continuous glucose monitoring ready for prime time in the cardiac care unit. *Coron Artery Dis.* 2007 Aug;18(5):405-9. doi: 10.1097/MCA.0b013e328224bb02. PubMed PMID: 17627191.
123. Singaram V, **Pratley R.** The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?. *Diab Vasc Dis Res.* 2007 Sep;4(3):237-40. doi: 10.3132/dvdr.2007.047. Review. PubMed PMID: 17907116.
124. **Pratley RE,** Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. *Diabetes Care.* 2007 Dec;30(12):3017-22. doi: 10.2337/dc07-1188. Epub 2007 Sep 18. PubMed PMID: 17878242.
125. Jackman MR, Ravussin E, Rowe MJ, **Pratley R,** Milner MR, Willis WT. Effect of a polymorphism in the ND1 mitochondrial gene on human skeletal muscle mitochondrial function. *Obesity (Silver Spring).* 2008 Feb;16(2):363-8. doi: 10.1038/oby.2007.40. PubMed PMID: 18239645.
126. Gilbert M, **Pratley RE.** LAP-BAND or medical therapy for metabolic syndrome?. *Curr Diab Rep.* 2008 Feb;8(1):5-6. PubMed PMID: 18366991.
127. Ahrén B, **Pratley RE,** Soubt M, Dunning BE, Foley JE. Clinical measures of islet function: usefulness to characterize defects in diabetes. *Curr Diabetes Rev.* 2008 May;4(2):129-45. Review. PubMed PMID: 18473760.
128. Toth MJ, Cooper BC, **Pratley RE,** Mari A, Matthews DE, Casson PR. Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion. *Am J Physiol Endocrinol Metab.* 2008 Jun;294(6):E1035-45. doi: 10.1152/ajpendo.00789.2007. Epub 2008 Apr 15. PubMed PMID: 18413671; PubMed Central PMCID: PMC2435411.
129. Lee YH, Tharp WG, Maple RL, Nair S, Permana PA, **Pratley RE.** Amyloid precursor protein expression is upregulated in adipocytes in obesity. *Obesity (Silver Spring).* 2008 Jul;16(7):1493-500. doi: 10.1038/oby.2008.267. Epub 2008 May 15. PubMed PMID: 18483477.
130. **Pratley RE.** Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. *Medscape J Med.* 2008 Jul 28;10(7):171. Review. PubMed PMID: 18769687; PubMed Central PMCID: PMC2525460.
131. Tharp WG, Lee YH, Maple RL, **Pratley RE.** The cannabinoid CB1 receptor is expressed in pancreatic delta-cells. *Biochem Biophys Res Commun.* 2008 Aug 8;372(4):595-600. doi: 10.1016/j.bbrc.2008.05.077. Epub 2008 May 27. PubMed PMID: 18505678.
132. **Pratley RE,** Gilbert M. Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors. *Rev Diabet Stud.* 2008 Summer;5(2):73-94. doi: 10.1900/RDS.2008.5.73. Epub 2008 Aug 10. PubMed PMID: 18795210; PubMed Central PMCID: PMC2556445.

133. **Pratley RE**, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. *Diabetes Obes Metab*. 2008 Sep;10(10):931-8. doi: 10.1111/j.1463-1326.2007.00835.x. Epub 2007 Dec 17. PubMed PMID: 18093207.
134. **Pratley RE**. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes. *J Am Acad Nurse Pract*. 2008 Nov;20 Suppl 1:7-11. Review. PubMed PMID: 19402254.
135. **Pratley RE**. Expanding treatment options for type 2 diabetes: the old and the new. *Diabetes Educ*. 2009 Jan-Feb;35 Suppl 1:4S-11S. doi: 10.1177/0145721709331522. PubMed PMID: 19218561.
136. D'Alessio DA, Denney AM, Hermiller LM, Prigeon RL, Martin JM, Tharp WG, Saylan ML, He Y, Dunning BE, Foley JE, **Pratley RE**. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. *J Clin Endocrinol Metab*. 2009 Jan;94(1):81-8. doi: 10.1210/jc.2008-1135. Epub 2008 Oct 28. PubMed PMID: 18957505; PubMed Central PMCID: PMC2630874.
137. **Pratley RE**. Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. *Expert Opin Pharmacother*. 2009 Feb;10(3):503-12. doi: 10.1517/14656560802694713. Review. PubMed PMID: 19191685.
138. Carlson A, **Pratley RE**. Weight loss and diets: which diet works best?. *Curr Diab Rep*. 2009 Feb;9(1):35-6. PubMed PMID: 19192422.
139. **Pratley RE**, Kipnes MS, Fleck PR, Wilson C, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. *Diabetes Obes Metab*. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x. PubMed PMID: 19125778.
140. Gilbert MP, **Pratley RE**. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. *Am J Med*. 2009 Jun;122(6 Suppl):S11-24. doi: 10.1016/j.amjmed.2009.03.013. Review. PubMed PMID: 19464424.
141. Gilbert MP, **Pratley RE**. Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus. *Eur J Intern Med*. 2009 Jul;20 Suppl 2:S309-18. doi: 10.1016/j.ejim.2009.05.011. Epub 2009 Jun 21. Review. PubMed PMID: 19580950.
142. Lee YH, Martin JM, Maple RL, Tharp WG, **Pratley RE**. Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals. *Neuroendocrinology*. 2009;90(4):383-90. doi: 10.1159/000235555. Epub 2009 Aug 12. PubMed PMID: 19672057.
143. Blonde L, Dagogo-Jack S, Banerji MA, **Pratley RE**, Marcellari A, Braceras R, Purkayastha D, Baron M. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial--a primary care, type 2 diabetes study. *Diabetes Obes Metab*. 2009 Oct;11(10):978-86. doi: 10.1111/j.1463-1326.2009.01080.x. Epub 2009 Jul 13. PubMed PMID: 19614942.
144. **Pratley RE**, Reusch JE, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Curr Med Res Opin*. 2009 Oct;25(10):2361-71. doi: 10.1185/03007990903156111. PubMed PMID: 19650752.
145. **Pratley RE**, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. *J Am Geriatr Soc*. 2009 Nov;57(11):2011-9. doi: 10.1111/j.1532-5415.2009.02484.x. Epub 2009 Sep 30. PubMed PMID: 19793357.
146. Lee YH, Tharp WG, Dixon AE, Spaulding L, Trost S, Permana PA, **Pratley RE**. Dysregulation of Cannabinoid CB1 Receptor Expression in Subcutaneous Adipocytes of Obese Individuals. *Animal Cells and Systems*. 2009 December; 13(4):371-379.
147. Gilbert MP, **Pratley RE**. Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in the treatment of Type 2 Diabetes. *Hot Topics in Cardiometabolic Disorders*. 2010; 2.
148. Matfin G, **Pratley RE**. Advances in the treatment of prediabetes. *Ther Adv Endocrinol Metab*. 2010 Feb;1(1):5-14. doi: 10.1177/2042018810366429. PubMed PMID: 23148144; PubMed Central PMCID: PMC3474610.
149. **Pratley RE**. Obesity: A Chronic Inflammatory Condition. *CADRE Newsletter*. Spring 2010; 8(3).

150. **Pratley RE**, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010 Apr 24;375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8. PubMed PMID: 20417856.
151. Villa J, **Pratley RE**. Ezetimibe/simvastatin or atorvastatin for the treatment of hypercholesterolemia in patients with the metabolic syndrome: the VYMET study. *Curr Diab Rep*. 2010 Jun;10(3):173-5. doi: 10.1007/s11892-010-0107-5. PubMed PMID: 20425579.
152. **Pratley RE**. GIP: an inconsequential incretin or not?. *Diabetes Care*. 2010 Jul;33(7):1691-2. doi: 10.2337/dc10-0704. PubMed PMID: 20587731; PubMed Central PMCID: PMC2890383.
153. Dixon AE, Holguin F, Sood A, Salome CM, **Pratley RE**, Beuther DA, Celedón JC, Shore SA. An official American Thoracic Society Workshop report: obesity and asthma. *Proc Am Thorac Soc*. 2010 Sep;7(5):325-35. doi: 10.1513/pats.200903-013ST. PubMed PMID: 20844291.
154. Jumpertz R, Guijarro A, **Pratley RE**, Piomelli D, Krakoff J. Central and peripheral endocannabinoids and cognate acylethanolamides in humans: association with race, adiposity, and energy expenditure. *J Clin Endocrinol Metab*. 2011 Mar;96(3):787-91. doi: 10.1210/jc.2010-2028. Epub 2010 Dec 22. PubMed PMID: 21177788; PubMed Central PMCID: PMC3047230.
155. Davies M, **Pratley R**, Hammer M, Thomsen AB, Cuddihy R. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. *Diabet Med*. 2011 Mar;28(3):333-7. doi: 10.1111/j.1464-5491.2010.03074.x. PubMed PMID: 21309842.
156. Jaworski DM, Sideleva O, Stradecki HM, Langlois GD, Habibovic A, Satish B, Tharp WG, Lausier J, Larock K, Jetton TL, Peshavaria M, **Pratley RE**. Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice. *Endocrinology*. 2011 Apr;152(4):1300-13. doi: 10.1210/en.2010-1029. Epub 2011 Feb 1. PubMed PMID: 21285317; PubMed Central PMCID: PMC3060627.
157. **Pratley R**, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. *Int J Clin Pract*. 2011 Apr;65(4):397-407. doi: 10.1111/j.1742-1241.2011.02656.x. Epub 2011 Mar 1. PubMed PMID: 21355967; PubMed Central PMCID: PMC3085127.
158. Schneider A, **Pratley RE**. Does the metabolic syndrome carry additional risk for myocardial infarction?. *Curr Diab Rep*. 2011 Jun;11(3):149-50. doi: 10.1007/s11892-011-0181-3. PubMed PMID: 21336844.
159. Power M, **Pratley R**. Alternative and complementary treatments for metabolic syndrome. *Curr Diab Rep*. 2011 Jun;11(3):173-8. doi: 10.1007/s11892-011-0184-0. Review. PubMed PMID: 21336843.
160. Villa J, **Pratley RE**. Adipose tissue dysfunction in polycystic ovary syndrome. *Curr Diab Rep*. 2011 Jun;11(3):179-84. doi: 10.1007/s11892-011-0189-8. Review. PubMed PMID: 21424395.
161. Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, **Pratley RE**, Huber K, Wolk R, Krishnaswami A, Frye RL. Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Circulation*. 2011 Aug 9;124(6):695-703. doi: 10.1161/CIRCULATIONAHA.110.014860. Epub 2011 Jul 18. PubMed PMID: 21768545; PubMed Central PMCID: PMC4220292.
162. Dixon AE, **Pratley RE**, Forgione PM, Kaminsky DA, Whittaker-Leclair LA, Griffes LA, Garudathri J, Raymond D, Poynter ME, Bunn JY, Irvin CG. Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. *J Allergy Clin Immunol*. 2011 Sep;128(3):508-15.e1-2. doi: 10.1016/j.jaci.2011.06.009. Epub 2011 Jul 23. PubMed PMID: 21782230; PubMed Central PMCID: PMC3164923.
163. Henry RR, Buse JB, Sesti G, Davies MJ, Jensen KH, Brett J, **Pratley RE**. Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. *Endocr Pract*. 2011 Nov-Dec;17(6):906-13. PubMed PMID: 22193143.
164. Bode BW, Brett J, Falahati A, **Pratley RE**. Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥ 65 and < 65 years of age: a pooled analysis from phase III studies. *Am J Geriatr Pharmacother*. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4. PubMed PMID: 22055210.

165. Tharp WG, Lee YH, Greene SM, Vincelle E, Beach TG, **Pratley RE**. Measurement of altered A β PP isoform expression in frontal cortex of patients with Alzheimer's disease by absolute quantification real-time PCR. *J Alzheimers Dis*. 2012;29(2):449-57. doi: 10.3233/JAD-2011-111337. PubMed PMID: 22258516; PubMed Central PMCID: PMC3325610.
166. **Pratley RE**, Gilbert M. Clinical management of elderly patients with type 2 diabetes mellitus. *Postgrad Med*. 2012 Jan;124(1):133-43. doi: 10.3810/pgm.2012.01.2526. Review. PubMed PMID: 22314123.
167. Mazza AD, **Pratley RE**, Smith SR. Beta-cell preservation...Is weight loss the answer?. *Rev Diabet Stud*. 2011 Winter;8(4):446-53. doi: 10.1900/RDS.2011.8.446. Epub 2012 Feb 10. Review. PubMed PMID: 22580726; PubMed Central PMCID: PMC3359689.
168. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, **Pratley RE**. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. *J Clin Endocrinol Metab*. 2012 May;97(5):1615-22. doi: 10.1210/jc.2011-2243. Epub 2012 Mar 14. PubMed PMID: 22419732.
169. Jumpertz R, Guijarro A, **Pratley RE**, Mason CC, Piomelli D, Krakoff J. Associations of fatty acids in cerebrospinal fluid with peripheral glucose concentrations and energy metabolism. *PLoS One*. 2012;7(7):e41503. doi: 10.1371/journal.pone.0041503. Epub 2012 Jul 24. PubMed PMID: 22911803; PubMed Central PMCID: PMC3404019.
170. Sideleva O, Suratt BT, Black KE, Tharp WG, **Pratley RE**, Forgione P, Dienz O, Irvin CG, Dixon AE. Obesity and asthma: an inflammatory disease of adipose tissue not the airway. *Am J Respir Crit Care Med*. 2012 Oct 1;186(7):598-605. doi: 10.1164/rccm.201203-0573OC. Epub 2012 Jul 26. PubMed PMID: 22837379; PubMed Central PMCID: PMC3480522.
171. **Pratley RE**, Nauck MA, Bailey T, Montanya E, Filetti S, Garber AJ, Thomsen AB, Furber S, Davies M. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. *Diabetes Care*. 2012 Oct;35(10):1986-93. doi: 10.2337/dc11-2113. Epub 2012 Jul 30. PubMed PMID: 22851600; PubMed Central PMCID: PMC3447855.
172. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, **Pratley RE**, Swift CS. Diabetes in older adults. *Diabetes Care*. 2012 Dec;35(12):2650-64. doi: 10.2337/dc12-1801. Epub 2012 Oct 25. PubMed PMID: 23100048; PubMed Central PMCID: PMC3507610.
173. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, **Pratley RE**, Swift CS. Diabetes in older adults: a consensus report. *J Am Geriatr Soc*. 2012 Dec;60(12):2342-56. doi: 10.1111/jgs.12035. Epub 2012 Oct 25. PubMed PMID: 23106132; PubMed Central PMCID: PMC4525769.
174. King AB, Montanya E, **Pratley RE**, Blonde L, Svendsen CB, Donsmark M, Sesti G. Liraglutide achieves A1C targets more often than sitagliptin or exenatide when added to metformin in patients with type 2 diabetes and a baseline A1C <8.0%. *Endocr Pract*. 2013 Jan-Feb;19(1):64-72. doi: 10.4158/EP12232.OR. PubMed PMID: 23186975.
175. **Pratley RE**, Urosevic D, Boldrin M, Balena R. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6). *Diabetes Obes Metab*. 2013 Mar;15(3):234-40. doi: 10.1111/dom.12009. Epub 2012 Sep 30. PubMed PMID: 22958426.
176. White WB, **Pratley R**, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus. *Diabetes Obes Metab*. 2013 Jul;15(7):668-73. doi: 10.1111/dom.12093. Epub 2013 Apr 4. PubMed PMID: 23489301.
177. **Pratley RE**. Pathophysiology of the Incretin Pathways in Type 2 Diabetes. *Dialogues in Diabetes*. 2013 September; 3(1):10-13.
178. **Pratley RE**. Type 2 diabetes is one of the leading causes of premature morbidity and mortality. Introduction. *Am J Med*. 2013 Sep;126(9 Suppl 1):S1. doi: 10.1016/j.amjmed.2013.06.008. PubMed PMID: 23953073.
179. **Pratley RE**. The early treatment of type 2 diabetes. *Am J Med*. 2013 Sep;126(9 Suppl 1):S2-9. doi: 10.1016/j.amjmed.2013.06.007. PubMed PMID: 23953075.

180. Kim J, Jeong JI, Kim KM, Choi I, **Pratley RE**, Lee Y. Improved glucose tolerance with restored expression of glucose transporter 4 in C57BL/6 mice after a long period of high-fat diet feeding. *Animal Cells and Systems*. 2014; 18(3):197-203. doi: 10.1080/19768354.2014.924995.
181. Jeong JK, Kim J, Kim KM, Choi I, **Pratley RE**, Lee Y. Altered gene expression of amyloid precursor protein in the adipose tissue and brain of obese mice fed with long-term high-fat diet and streptozotocin-induced diabetic mice. *Animal Cells and Systems*. 2014; 18(4):219-227. doi: 10.1080/19768354.2014.940383.
182. **Pratley RE**, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. *Lancet Diabetes Endocrinol*. 2014 Apr;2(4):289-97. doi: 10.1016/S2213-8587(13)70214-6. Epub 2014 Feb 6. PubMed PMID: 24703047.
183. Kyriazis GA, Smith KR, Tyrberg B, Hussain T, **Pratley RE**. Sweet taste receptors regulate basal insulin secretion and contribute to compensatory insulin hypersecretion during the development of diabetes in male mice. *Endocrinology*. 2014 Jun;155(6):2112-21. doi: 10.1210/en.2013-2015. Epub 2014 Apr 8. PubMed PMID: 24712876; PubMed Central PMCID: PMC4020927.
184. **Pratley RE**. The efficacy and effectiveness of drugs for diabetes: how do clinical trials and the real world compare? *Diabetologia*. 2014 Jul;57(7):1273-5. doi: 10.1007/s00125-014-3263-3. Epub 2014 May 22. PubMed PMID: 24849569.
185. **Pratley RE**, Heller SR, Miller MA. Treatment of type 2 diabetes mellitus in the older adult: a review. *Endocr Pract*. 2014 Jul;20(7):722-36. doi: 10.4158/EP13192.RA. Review. PubMed PMID: 24518176.
186. **Pratley RE**, Fleck P, Wilson C. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study. *Diabetes Obes Metab*. 2014 Jul;16(7):613-21. doi: 10.1111/dom.12258. Epub 2014 Feb 12. PubMed PMID: 24400655.
187. **Pratley RE**. Linagliptin use in older individuals with type 2 diabetes. *Clin Interv Aging*. 2014;9:1109-14. doi: 10.2147/CIA.S62877. eCollection 2014. Review. PubMed PMID: 25083132; PubMed Central PMCID: PMC4108453.
188. **Pratley RE**, Kuritzky L, Tenzer P. A patient-centered approach to managing patients with type 2 diabetes. *Am J Med*. 2014 Nov;127(11):e15-6. doi: 10.1016/j.amjmed.2014.10.007. Epub 2014 Oct 15. PubMed PMID: 25447628.
189. Weissman PN, Carr MC, Ye J, Cirkel DT, Stewart M, Perry C, **Pratley R**. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. *Diabetologia*. 2014 Dec;57(12):2475-84. doi: 10.1007/s00125-014-3360-3. Epub 2014 Sep 11. PubMed PMID: 25208756.
190. Gilbert MP, **Pratley RE**. The impact of diabetes and diabetes medications on bone health. *Endocr Rev*. 2015 Apr;36(2):194-213. doi: 10.1210/er.2012-1042. Epub 2015 Mar 4. Review. PubMed PMID: 25738213.
191. Kien CL, Bunn JY, Fukagawa NK, Anathy V, Matthews DE, Crain KI, Ebenstein DB, Tarleton EK, **Pratley RE**, Poynter ME. Lipidomic evidence that lowering the typical dietary palmitate to oleate ratio in humans decreases the leukocyte production of proinflammatory cytokines and muscle expression of redox-sensitive genes. *J Nutr Biochem*. 2015 Dec;26(12):1599-606. doi: 10.1016/j.jnutbio.2015.07.014. Epub 2015 Aug 1. PubMed PMID: 26324406; PubMed Central PMCID: PMC4679618.
192. Wolk R, Bertolet M, Brooks MM, **Pratley RE**, Sobel BE, Frye RL, Singh P, Calvin AD, Rutter MK, Mooradian AD, Somers VK. Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D trial. *Eur J Prev Cardiol*. 2016 Jan;23(1):50-8. doi: 10.1177/2047487314544046. Epub 2014 Jul 29. PubMed PMID: 25073857; PubMed Central PMCID: PMC4385003.
193. Weinstock RS, DuBose SN, Bergenstal RM, Chaytor NS, Peterson C, Olson BA, Munshi MN, Perrin AJ, Miller KM, Beck RW, Liljenquist DR, Aleppo G, Buse JB, Kruger D, Bhargava A, Golland RS, Edelen RC, **Pratley RE**, Peters AL, Rodriguez H, Ahmann AJ, Lock JP, Garg SK, Rickels MR, Hirsch IB. Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes. *Diabetes Care*. 2016 Apr;39(4):603-10. doi: 10.2337/dc15-1426. Epub 2015 Dec 17. PubMed PMID: 26681721.
194. Gilbert MP, Marre M, Holst JJ, Garber A, Baeres FM, Thomsen H, **Pratley RE**. Comparison Of The Long-Term Effects Of Liraglutide And Glimperide Monotherapy On Bone Mineral Density In Patients With Type

- 2 Diabetes. *Endocr Pract*. 2016 Apr;22(4):406-11. doi: 10.4158/EP15758.OR. Epub 2015 Nov 17. PubMed PMID: 26574791.
195. Kovacova Z, Tharp WG, Liu D, Wei W, Xie H, Collins S, **Pratley RE**. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. *Obesity (Silver Spring)*. 2016 Apr;24(4):820-8. doi: 10.1002/oby.21418. Epub 2016 Feb 17. PubMed PMID: 26887289; PubMed Central PMCID: PMC5067565.
196. Smith KR, Hussain T, Karimian Azari E, Steiner JL, Ayala JE, **Pratley RE**, Kyriazis GA. Disruption of the sugar-sensing receptor T1R2 attenuates metabolic derangements associated with diet-induced obesity. *Am J Physiol Endocrinol Metab*. 2016 Apr 15;310(8):E688-E698. doi: 10.1152/ajpendo.00484.2015. Epub 2016 Feb 16. PubMed PMID: 26884387; PubMed Central PMCID: PMC4835941.
197. Tharp WG, Gupta D, Smith J, Jones KP, Jones AM, **Pratley RE**. Effects of glucose and insulin on secretion of amyloid- β by human adipose tissue cells. *Obesity (Silver Spring)*. 2016 Jul;24(7):1471-9. doi: 10.1002/oby.21494. Epub 2016 May 13. PubMed PMID: 27172814; PubMed Central PMCID: PMC5084817.
198. Wolk R, Bertolet M, Singh P, Brooks MM, **Pratley RE**, Frye RL, Mooradian AD, Rutter MK, Calvin AD, Chaitman BR, Somers VK. Prognostic Value of Adipokines in Predicting Cardiovascular Outcome: Explaining the Obesity Paradox. *Mayo Clin Proc*. 2016 Jul;91(7):858-66. doi: 10.1016/j.mayocp.2016.03.020. Epub 2016 Jun 9. PubMed PMID: 27289411; PubMed Central PMCID: PMC4935584.
199. Seyhan AA, Nunez Lopez YO, Xie H, Yi F, Mathews C, Pasarica M, **Pratley RE**. Pancreas-enriched miRNAs are altered in the circulation of subjects with diabetes: a pilot cross-sectional study. *Sci Rep*. 2016 Aug 25;6:31479. doi: 10.1038/srep31479. PubMed PMID: 27558530; PubMed Central PMCID: PMC4997329.
200. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, **Pratley RE**, Haahr PM, Lange M, Frandsen KB, Rabøl R, Buse JB. Design of DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) - DEVOTE 1. *Am Heart J*. 2016 Sep;179:175-83. doi: 10.1016/j.ahj.2016.06.004. Epub 2016 Jun 18. PubMed PMID: 27595693.
201. Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, **Pratley RE**, Schwartz GG, Kernan WN. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. *Diabetes Care*. 2016 Oct;39(10):1684-92. doi: 10.2337/dc16-0798. Epub 2016 Jul 27. PubMed PMID: 27465265; PubMed Central PMCID: PMC5033078.
202. Satman I, Rea R, Eriksson M, Mosenzon O, **Pratley R**, Baeres F, D Ørsted D, Mann J. LEADER-6: Baseline renal function and associated factors in a high cardiovascular risk type 2 diabetes population. *J Diabetes Complications*. 2016 Nov - Dec;30(8):1631-1639. doi: 10.1016/j.jdiacomp.2016.06.001. Epub 2016 Jun 3. PubMed PMID: 27320184.
203. **Pratley RE**. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?. *Diabetes Technol Ther*. 2016 Nov;18(11):671-673. doi: 10.1089/dia.2016.0339. PubMed PMID: 27860501.
204. Inzucchi SE, Viscoli CM, Young LH, Furie KL, Gorman M, Lovejoy AM, Dagogo-Jack S, Ismail-Beigi F, Korytkowski MT, **Pratley RE**, Schwartz GG, Kernan WN. Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. *Diabetes Care* 2016;39:1684-1692. *Diabetes Care*. 2017 Apr;40(4):e47-e48. doi: 10.2337/dci16-0048. PubMed PMID: 28325804; PubMed Central PMCID: PMC5360290.
205. Karimian Azari E, Smith KR, Yi F, Osborne TF, Bizzotto R, Mari A, **Pratley RE**, Kyriazis GA. Inhibition of sweet chemosensory receptors alters insulin responses during glucose ingestion in healthy adults: a randomized crossover interventional study. *Am J Clin Nutr*. 2017 Apr;105(4):1001-1009. doi: 10.3945/ajcn.116.146001. Epub 2017 Mar 1. PubMed PMID: 28251932; PubMed Central PMCID: PMC5366051.
206. Khalid S, Bilal A, Asad-Ur-Rahman FNU, **Pratley R**. Postgastric bypass hypoglycaemia in a patient with end-stage renal disease: a diagnostic and management pitfall. *BMJ Case Rep*. 2017 Jun 15;2017. doi: 10.1136/bcr-2017-220600. PubMed PMID: 28619742; PubMed Central PMCID: PMC5535128.

207. **Pratley RE**, Cersosimo E. Use of Canagliflozin in Combination With and Compared to Incretin-Based Therapies in Type 2 Diabetes. *Clin Diabetes*. 2017 Jul;35(3):141-153. doi: 10.2337/cd16-0063. PubMed PMID: 28761216; PubMed Central PMCID: PMC5510927.
208. Driscoll KA, Corbin KD, Maahs DM, **Pratley R**, Bishop FK, Kahkoska A, Hood KK, Mayer-Davis E. Biopsychosocial Aspects of Weight Management in Type 1 Diabetes: a Review and Next Steps. *Curr Diab Rep*. 2017 Aug;17(8):58. doi: 10.1007/s11892-017-0892-1. Review. PubMed PMID: 28660565; PubMed Central PMCID: PMC6053070.
209. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, **Pratley RE**, Haahr PM, Lange M, Brown-Frandsen K, Moses A, Skibsted S, Kvist K, Buse JB. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med*. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12. PubMed PMID: 28605603; PubMed Central PMCID: PMC5731244.
210. Nunez Lopez YO, Pittas AG, **Pratley RE**, Seyhan AA. Circulating levels of miR-7, miR-152 and miR-192 respond to vitamin D supplementation in adults with prediabetes and correlate with improvements in glycemic control. *J Nutr Biochem*. 2017 Nov;49:117-122. doi: 10.1016/j.jnutbio.2017.08.007. Epub 2017 Aug 26. PubMed PMID: 28945992.
211. Pieber TR, Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, **Pratley RE**, Woo V, Heller S, Lange M, Brown-Frandsen K, Moses A, Barner Lekdorf J, Lehmann L, Kvist K, Buse JB. DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality. *Diabetologia*. 2018 Jan;61(1):58-65. doi: 10.1007/s00125-017-4422-0. Epub 2017 Sep 15. PubMed PMID: 28913543; PubMed Central PMCID: PMC6002964.
212. Zinman B, Marso SP, Poulter NR, Emerson SS, Pieber TR, **Pratley RE**, Lange M, Brown-Frandsen K, Moses A, Ocampo Francisco AM, Barner Lekdorf J, Kvist K, Buse JB. Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2). *Diabetologia*. 2018 Jan;61(1):48-57. doi: 10.1007/s00125-017-4423-z. Epub 2017 Sep 15. PubMed PMID: 28913575; PubMed Central PMCID: PMC6002963.
213. Heller SR, **Pratley RE**, Sinclair A, Festa A, Kiljański J, Brusko CS, Duan R, Heine RJ. Glycaemic outcomes of an Individualized treatment approach for older vulnerable patients: A randomized, controlled study in type 2 diabetes Mellitus (IMPERIUM). *Diabetes Obes Metab*. 2018 Jan;20(1):148-156. doi: 10.1111/dom.13051. Epub 2017 Aug 8. PubMed PMID: 28671753; PubMed Central PMCID: PMC5724506.
214. Dittus KL, Harvey JR, Bunn JY, Kokinda ND, Wilson KM, Priest J, **Pratley RE**. Impact of a behaviorally-based weight loss intervention on parameters of insulin resistance in breast cancer survivors. *BMC Cancer*. 2018 Mar 27;18(1):351. doi: 10.1186/s12885-018-4272-2. PubMed PMID: 29587682; PubMed Central PMCID: PMC5872579.
215. **Pratley RE**, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, Viljoen A. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. *Lancet Diabetes Endocrinol*. 2018 Apr;6(4):275-286. doi: 10.1016/S2213-8587(18)30024-X. Epub 2018 Feb 1. PubMed PMID: 29397376.
216. **Pratley RE**, Eldor R, Raji A, Golm G, Huyck SB, Qiu Y, Sunga S, Johnson J, Terra SG, Mancuso JP, Engel SS, Lauring B. Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial. *Diabetes Obes Metab*. 2018 May;20(5):1111-1120. doi: 10.1111/dom.13194. Epub 2018 Jan 25. PubMed PMID: 29266675; PubMed Central PMCID: PMC5947297.
217. Porksen NK, Linnebjerg H, Lam ECQ, Garhyan P, Pachori A, **Pratley RE**, Smith SR. Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus. *Diabetes Obes Metab*. 2018 May;20(5):1193-1201. doi: 10.1111/dom.13215. Epub 2018 Feb 4. PubMed PMID: 29316143.
218. Verma S, Bhatt DL, Bain SC, Buse JB, Mann JFE, Marso SP, Nauck MA, Poulter NR, **Pratley RE**, Zinman B, Michelsen MM, Monk Fries T, Rasmussen S, Leiter LA. Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial. *Circulation*. 2018 May 15;137(20):2179-2183. doi: 10.1161/CIRCULATIONAHA.118.033898. PubMed PMID: 29760228.
219. Nunez Lopez YO, Messi ML, **Pratley RE**, Zhang T, Delbono O. Troponin T3 associates with DNA consensus sequence that overlaps with p53 binding motifs. *Exp Gerontol*. 2018 Jul 15;108:35-40. doi:

- 10.1016/j.exger.2018.03.012. Epub 2018 Mar 27. PubMed PMID: 29596868; PubMed Central PMCID: PMC5994179.
220. LeBlanc ES, **Pratley RE**, Dawson-Hughes B, Staten MA, Sheehan PR, Lewis MR, Peters A, Kim SH, Chatterjee R, Aroda VR, Chadha C, Neff LM, Brodsky IG, Rosen C, Desouza CV, Foreyt JP, Hsia DS, Johnson KC, Raskin P, Kashyap SR, O'Neil P, Phillips LS, Rasouli N, Liao EP, Robbins DC, Pittas AG. Baseline Characteristics of the Vitamin D and Type 2 Diabetes (D2d) Study: A Contemporary Prediabetes Cohort That Will Inform Diabetes Prevention Efforts. *Diabetes Care*. 2018 Aug;41(8):1590-1599. doi: 10.2337/dc18-0240. Epub 2018 Jun 25. PubMed PMID: 29941495; PubMed Central PMCID: PMC6054501.
221. Bilal A, **Pratley RE**. Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial. *Curr Diab Rep*. 2018 Sep 18;18(11):102. doi: 10.1007/s11892-018-1086-1. Review. PubMed PMID: 30229352.
222. Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, **Pratley RE**. The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial. *Diabetes Care*. 2018 Oct;41(10):2229-2235. doi: 10.2337/dc18-1094. Epub 2018 Aug 2. PubMed PMID: 30072400; PubMed Central PMCID: PMC6150424.
223. **Pratley RE**. Implications of cardiovascular outcome trials with injectable antidiabetic agents. *J Diabetes*. 2018 Oct;10(10):801-803. doi: 10.1111/1753-0407.12792. Epub 2018 Jul 4. PubMed PMID: 29971941.
224. Corbin KD, Driscoll KA, **Pratley RE**, Smith SR, Maahs DM, Mayer-Davis EJ. Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms. *Endocr Rev*. 2018 Oct 1;39(5):629-663. doi: 10.1210/er.2017-00191. Review. PubMed PMID: 30060120.
225. Stephens NA, Brouwers B, Eroshkin AM, Yi F, Cornell HH, Meyer C, Goodpaster BH, **Pratley RE**, Smith SR, Sparks LM. Exercise Response Variations in Skeletal Muscle PCr Recovery Rate and Insulin Sensitivity Relate to Muscle Epigenomic Profiles in Individuals With Type 2 Diabetes. *Diabetes Care*. 2018 Oct;41(10):2245-2254. doi: 10.2337/dc18-0296. Epub 2018 Aug 2. PubMed PMID: 30072402.
226. Cousminer DL, Ahlqvist E, Mishra R, Andersen MK, Chesi A, Hawa MI, Davis A, Hodge KM, Bradfield JP, Zhou K, Guy VC, Åkerlund M, Wod M, Fritsche LG, Vestergaard H, Snyder J, Højlund K, Linneberg A, Käräjämäki A, Brandslund I, Kim CE, Witte D, Sørgjerd EP, Brillion DJ, Pedersen O, Beck-Nielsen H, Grarup N, **Pratley RE**, Rickels MR, Vella A, Ovalle F, Melander O, Harris RI, Varvel S, Grill VER, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Åsvold BO, Yderstræde KB, Pearson ER, Schwartz S, Voight BF, Hansen T, Tuomi T, Boehm BO, Groop L, Leslie RD, Grant SFA. First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. *Diabetes Care*. 2018 Nov;41(11):2396-2403. doi: 10.2337/dc18-1032. Epub 2018 Sep 25. PubMed PMID: 30254083; PubMed Central PMCID: PMC6196829.
227. Smith K, Karimian Azari E, LaMoia TE, Hussain T, Vargova V, Karolyi K, Veldhuis PP, Arnoletti JP, de la Fuente SG, **Pratley RE**, Osborne TF, Kyriazis GA. T1R2 receptor-mediated glucose sensing in the upper intestine potentiates glucose absorption through activation of local regulatory pathways. *Mol Metab*. 2018 Nov;17:98-111. doi: 10.1016/j.molmet.2018.08.009. Epub 2018 Aug 27. PubMed PMID: 30201274; PubMed Central PMCID: PMC6197762.
228. **Pratley RE**, Rosenstock J, Heller SR, Sinclair A, Heine RJ, Kiljański J, Brusko CS, Duan R, Festa A. Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus. *J Diabetes Sci Technol*. 2018 Nov;12(6):1184-1191. doi: 10.1177/1932296818776993. Epub 2018 Jun 12. PubMed PMID: 29893144; PubMed Central PMCID: PMC6232729.
229. Cannon CP, McGuire DK, **Pratley R**, Dagogo-Jack S, Mancuso J, Huyck S, Charbonnel B, Shih WJ, Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG. Design and baseline characteristics of the eValuation of ERTugliflozin efficacy and Safety CardioVascular outcomes trial (VERTIS-CV). *Am Heart J*. 2018 Dec;206:11-23. doi: 10.1016/j.ahj.2018.08.016. Epub 2018 Sep 5. PubMed PMID: 30290289.
230. Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, Nauck MA, **Pratley RE**, Zinman B, Ørsted DD, Monk Fries T, Rasmussen S, Marso SP. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. *Circulation*. 2018 Dec 18;138(25):2884-2894. doi: 10.1161/CIRCULATIONAHA.118.034516. PubMed PMID: 30566004.

-
231. Nunez Lopez YO, Retnakaran R, Zinman B, **Pratley RE**, Seyhan AA. Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes. *Mol Metab.* 2019 Feb;20:63-78. doi: 10.1016/j.molmet.2018.11.003. Epub 2018 Nov 16. PubMed PMID:30503831; PubMed Central PMCID:PMC6358589.
232. Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, **Pratley R**, Réa RR, Kerr Saraiva JF, Rasmussen S, Tornøe K, von Scholten BJ, Buse JB. Effect of Liraglutide on Cardiovascular Outcomes in Elderly Patients: A Post Hoc Analysis of a Randomized Controlled Trial. *Ann Intern Med.* 2019 Mar 19;170(6):423-426. doi: 10.7326/M18-1569. Epub 2018 Dec 4. PubMed PMID: 30508430.
233. Brown-Frandsen K, Emerson SS, McGuire DK, Pieber TR, Poulter NR, **Pratley RE**, Zinman B, Ranthe MF, Grøn R, Lange M, Moses AC, Örsy P, Buse JB. Lower rates of cardiovascular events and mortality associated with liraglutide use in patients treated with basal insulin: A DEVOTE subanalysis (DEVOTE 10). *Diabetes Obes Metab.* 2019 Jun;21(6):1437-1444. doi: 10.1111/dom.13677. Epub 2019 Apr 1. PubMed PMID: 30793465; PubMed Central PMCID: PMC6504564.
234. Del Parigi A, Tang W, Liu D, Lee C, **Pratley R**. Machine Learning to Identify Predictors of Glycemic Control in Type 2 Diabetes: An Analysis of Target HbA1c Reduction Using Empagliflozin/Linagliptin Data. *Pharmaceut Med.* 2019 Jun;33(3):209-217. doi: 10.1007/s40290-019-00281-4. PubMed PMID: 31933292.
235. **Pratley RE**, Emerson SS, Franek E, Gilbert MP, Marso SP, McGuire DK, Pieber TR, Zinman B, Hansen CT, Hansen MV, Mark T, Moses AC, Buse JB. Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7). *Diabetes Obes Metab.* 2019 Jul;21(7):1625-1633. doi: 10.1111/dom.13699. Epub 2019 Apr 15. PubMed PMID: 30850995; PubMed Central PMCID: PMC6617815.
236. Verma S, Bain SC, Monk Fries T, Mazer CD, Nauck MA, **Pratley RE**, Rasmussen S, Saevereid HA, Zinman B, Buse JB. Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials. *Diabetes Obes Metab.* 2019 Jul;21(7):1745-1751. doi: 10.1111/dom.13698. Epub 2019 Apr 2. PubMed PMID: 30851070; PubMed Central PMCID: PMC6619033.
237. Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, **Pratley R**, Sathyapalan T, Desouza C. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. *Lancet Diabetes Endocrinol.* 2019 Jul;7(7):515-527. doi: 10.1016/S2213-8587(19)30192-5. Epub 2019 Jun 9. PubMed PMID: 31189517.
238. **Pratley R**, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. *Lancet.* 2019 Jul 6;394(10192):39-50. doi: 10.1016/S0140-6736(19)31271-1. Epub 2019 Jun 8. PubMed PMID: 31186120.
239. Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Lewis MR, Liao E, Neff LM, Nelson J, O'Neil P, Park J, Peters A, Phillips LS, **Pratley R**, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M. Vitamin D Supplementation and Prevention of Type 2 Diabetes. *N Engl J Med.* 2019 Aug 8;381(6):520-530. doi: 10.1056/NEJMoa1900906. Epub 2019 Jun 7. PubMed PMID: 31173679.
240. Amod A, Buse JB, McGuire DK, Pieber TR, Pop-Busui R, **Pratley RE**, Zinman B, Hansen MB, Jia T, Mark T, Poulter NR. Glomerular Filtration Rate and Associated Risks of Cardiovascular Events, Mortality, and Severe Hypoglycemia in Patients with Type 2 Diabetes: Secondary Analysis (DEVOTE 11). *Diabetes Ther.* 2019 Oct 30;. doi: 10.1007/s13300-019-00715-x. [Epub ahead of print] PubMed PMID: 31667706.
241. Tack CJ, Jacob S, Desouza C, Bain SC, Buse JB, Nauck MA, Petrie JR, Poulter NR, **Pratley RE**, Stegmann HVBK, Bosch-Traberg H, Startseva E, Zinman B. Long-term efficacy and safety of combined insulin and glucagon-like peptide-1 therapy: Evidence from the LEADER trial. *Diabetes Obes Metab.* 2019 Nov;21(11):2450-2458. doi: 10.1111/dom.13826. Epub 2019 Jul 7. PubMed PMID: 31282028; PubMed Central PMCID: PMC6852575.
242. **Pratley RE**, Kang J, Trautmann ME, Hompesch M, Han O, Stewart J, Sorli CH, Jacob S, Yoon KH. Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study. *Diabetes Obes Metab.* 2019 Nov;21(11):2429-2439. doi: 10.1111/dom.13824. Epub 2019 Aug 13. PubMed PMID: 31264757; PubMed Central PMCID: PMC6851541.

243. Addala A, Igudesman D, Kahkoska AR, Muntis FR, Souris KJ, Whitaker KJ, **Pratley RE**, Mayer-Davis E. The interplay of type 1 diabetes and weight management: A qualitative study exploring thematic progression from adolescence to young adulthood. *Pediatr Diabetes*. 2019 Nov;20(7):974-985. doi: 10.1111/vedi.12903. Epub 2019 Aug 15. PubMed PMID: 31392807.
244. Pino MF, Stephens NA, Eroshkin AM, Yi F, Hodges A, Cornell HH, **Pratley RE**, Smith SR, Wang M, Han X, Coen PM, Goodpaster BH, Sparks LM. Endurance training remodels skeletal muscle phospholipid composition and increases intrinsic mitochondrial respiration in men with Type 2 diabetes. *Physiol Genomics*. 2019 Nov 1;51(11):586-595. doi: 10.1152/physiolgenomics.00014.2019. Epub 2019 Oct 7. PubMed PMID: 31588872.
245. **Pratley RE**, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, Møller DV, Zinman B. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. *Cardiovasc Diabetol*. 2019 Nov 15;18(1):156. doi: 10.1186/s12933-019-0960-8. PubMed PMID: 31729990; PubMed Central PMCID: PMC6858747.
246. Tharp WG, Gupta D, Sideleva O, Deacon CF, Holst JJ, Elahi D, **Pratley RE**. Effects of Pioglitazone on Glucose Dependent Insulinotropic Polypeptide Mediated Insulin Secretion and Adipocyte Receptor Expression in Patients with Type 2 Diabetes. *Diabetes*. 2020 Feb;69:146-157. doi: 10.2337/db18-1163. Epub 2019 Nov 22. PubMed PMID: 31757794.
247. Mishra R, Åkerlund M, Cousminer DL, Ahlqvist E, Bradfield JP, Chesi A, Hodge KM, Guy VC, Brillon DJ, **Pratley RE**, Rickels MR, Vella A, Ovalle F, Harris RI, Melander O, Varvel S, Hakonarson H, Froguel P, Lonsdale JT, Mauricio D, Schloot NC, Khunti K, Greenbaum CJ, Yderstræde KB, Tuomi T, Voight BF, Schwartz S, Boehm BO, Groop L, Leslie RD, Grant SFA. Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. *Diabetes Care*. 2019 Dec 16;. doi: 10.2337/dc19-0986. [Epub ahead of print] PubMed PMID: 31843946.
248. Carlson AL, Kanapka LG, Miller KM, Ahmann AJ, Chaytor NS, Fox S, Kiblinger L, Kruger D, Levy CJ, Peters AL, Rickels MR, Salam M, Shah VN, Young LA, Kudva YC, **Pratley R**. Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study. *J Diabetes Sci Technol*. 2019 Dec 21;1932296819894974. doi: 10.1177/1932296819894974. [Epub ahead of print] PubMed PMID: 31867988.
249. Rickels MR, Evans-Molina C, Bahnson HT, Ylescupidez A, Nadeau KJ, Hao W, Clements MA, Sherr JL, **Pratley RE**, Hannon TS, Shah VN, Miller KM, Greenbaum CJ. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. *J Clin Invest*. 2020 Jan 2;. doi: 10.1172/JCI134057. [Epub ahead of print] PubMed PMID: 31895699.
250. Shah VN, Bailey R, Wu M, Foster NC, Pop-Busui R, Katz M, Crandall J, Bacha F, Nadeau K, Libman I, Hiers P, Mizokami-Stout K, DiMeglio LA, Sherr J, **Pratley R**, Agarwal S, Snell-Bergeon J, Cengiz E, Polsky S, Mehta SN. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry. *J Clin Endocrinol Metab*. 2020 Jan 19;. doi: 10.1210/clinem/dgaa015. [Epub ahead of print] PubMed PMID: 31955209.
251. Mizokami-Stout KR, Li Z, Foster NC, Shah V, Aleppo G, McGill JB, **Pratley R**, Toschi E, Ang L, Pop-Busui R; for T1D Exchange Clinic Network; T1D Exchange Clinic Network. The Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes: Findings From the T1D Exchange. *Diabetes Care*. 2020 Feb 6;dc191583. doi: 10.2337/dc19-1583. Epub ahead of print. PMID: 32029635.

Book Chapters / Book Reviews

1. Pratley RE, Weyer C, Bogardus C. "Metabolic abnormalities in the development of type 2 diabetes mellitus." In: *Diabetes Mellitus: A Fundamental and Clinical Text*, 2nd edition. LeRoith D, Taylor SI, Olefsky JM, editors; Lippincott Williams & Wilkins: Philadelphia; 1999, pp 548-557.
2. Bogardus C, Baier L, Pratley R, Prochazka M, Hanson R. "Studies of the etiology of type 2 diabetes mellitus in Pima Indians." In: *Excerpta Medica International Congress Series*, Vol. 1181 (ICS 1181); Elsevier Science B.V.: Amsterdam, The Netherlands; 1999, pp 101-106.
3. Bogardus C, Ravussin E, Norman R, Pratley RE, Permana P, Prochazka M, Baier L, Bennett PH, Knowler WC, Hanson RL. "Genome-wide scan for obesity susceptibility genes in Pima Indians." In: *Progress in Obesity Research: 8*, Edited by Guy-Grand B and Ailhaud G, John Libby and Co. /8th 1999 Chapter 17, 129-134.

4. Pratley R. *Type 2 diabetes. Prediction and prevention*. Hitman GA, ed. John Wiley and Sons: Chichester. Brit J Nutr 83: 2000 (MDS), pp 335-336.

Abstracts

1. Pratley RE, Halter JB, Morady F. Role of electrophysiologic testing in elderly patients with syncope of undetermined origin. *J Am Geriatr Soc*. 1987 35:904.
2. Morady F, Halter J, Kou W, Nelson S, Pratley R, Schmaltz S, de Buitelir M. Electrophysiologic effects of epinephrine in humans. 60th Scientific Sessions of the American Heart Association, 1987.
3. Morady F, Halter J, Nelson S, Kou W, Pratley R, Schmaltz S, de Buitelir M. Alpha and beta-adrenergic electrophysiologic effects of epinephrine. 60th Scientific Sessions of the American Heart Association, 1987 Nov 16-19. Anaheim, CA.
4. Morady F, Nelson SD, Kou WH, Pratley R, Schmaltz S, de Buitelir M, Halter JB. Electrophysiologic effects of epinephrine in humans. *J Am Coll Cardiol*. 1988 Jun;11(6):1235-44. PMID: 2835408.
5. Pratley R, Coon P, Lumpkin M, Bleecker E, Goldberg A. Effects of weight loss and exercise training on norepinephrine (NE) response to upright posture in older men. *The Gerontologist*. 1988 28(Special Issue):142A.
6. Pratley R, Coon P, Drinkwater D, Goldberg A. Plasma insulin independently predicts blood pressure in older men. *The Gerontologist*. 1989 29: 5A.
7. Pratley R, Coon P, Bleecker E, Crawley B, Goldberg A. Weight loss (WL) or exercise training (ET) for obesity? Effects of risk factors for coronary artery disease (CAD). *Int J Obes*. 1989 13:520.
8. Pratley R, Coon P, Oriani J, Rogus E, Goldberg A. Euglycemic hyperinsulinemia increases plasma norepinephrine (NE) but not blood pressure in obese older men. *The Gerontologist*. 1990 30:185A.
9. Coon P, Pratley R, Rogus E, Goldberg A. Weight loss improves glucose metabolism in obese older men. *The Gerontologist*. 1990 30:18A.
10. Hurley BF, Redmond BA, Koffler KH, Menkes A, Hagberg JM, Pratley RE, Young J, Goldberg AP. Assessment of strength training effects on leg composition in older men by magnetic resonance imaging (MRI). *Med Sci in Sports and Exercise*. 1991 23:S108.
11. Haythornthwaite JA, Anderson DE, Pratley RE. The separate and combined effects of stress and high sodium intake on resting blood pressure. *Psychosom Med*. 1991 53(2):232.
12. Pratley R, Miller J, Rubin M, Smith A, Smith M, Nicklas B, Hurley B, Goldberg A. Resistive training decreases insulin resistance in healthy older men. *Clin Res*. 1992 40(2):196A.
13. Miller JP, Rubin MA, Smith AJ, Smith MM, Hurley BF, Goldberg AP, Pratley RE. Resistive training lowers insulin levels and increases insulin sensitivity in older men. *The Gerontologist*. 1992 32:201.
14. Boston JS, Karis GM, Pratley RE, Rogus EM, Goldberg AP. Hyperinsulinemia is not associated with hypertensive responses to exercise in normotensive older men. *The Gerontologist*. 1992 32:255.
15. Dengel DR, Pratley RE, Hagberg JM, Goldberg AP. Lower insulin sensitivity in older obese sedentary hypertensive vs. normotensive men. *The Gerontologist*. 1992 32:71.
16. Coon PJ, Pratley RE, Rogus EM, Goldberg AP. Physical fitness and insulin sensitivity in older lean men. *The Gerontologist*. 1992 32:137.
17. Miller JP, Rubin MA, Nicklas B, Smith MA, Goldberg AP, Hurley BF, Pratley RE. Strength training increases nonoxidative glucose metabolism in older men. *Med Sci Sports and Exercise*. 1993 May:25(5):S70.
18. Smith A, Smith M, Rubin M, Miller J, Nicklas B, Pratley R, Libanati C, Gundberg C, Hagberg J, Blackman M, Hurley B. Effects of strength training on bone mineral density: hormonal and bone turnover relationships. *Med Sci Sports and Exercise*. 1993 May:25(5):S188.
19. Hurley BF, Redmond BA, Pratley RE, Treuth MS, Rogers MA, Goldberg AP. Effects of strength training on muscle hypertrophy and muscle cell disruption in older men. *Int J Sports Med*. 1995 Aug;16(6):378-84. PMID: 7591389.
20. Dengel DR, Pratley RE, Goldberg AP. VO₂max and body composition are not exclusively responsible for the insulin resistance in older hypertensives. *Med Sci Sports and Exercise*. 1993 May:25(5):S142.

21. Smith M, Smith A, Rubin M, Miller J, Nicklas B, Pratley R, Goldberg AP, Hagberg J, Harman M, Hurley B. Effects of strength training on body composition in older men. *Med Sci Sports and Exercise*. 1993 May;25(5):S101.
22. Pratley R, Nicklas B, Miller J, Rubin M, Smith M, Smith A, Hurley B, Goldberg A. Strength training increases resting metabolic rate and plasma norepinephrine levels in healthy older men. *Clin Res*. 1993 41(2):A225.
23. Dengel DR, Pratley RE, Hagberg JM, Goldberg AP. Insulin deficiency and abdominal obesity, not increased insulin resistance are associated with NIDDM and glucose intolerance in hypertensive men. *Diabetes*. 1993 42(Suppl. 1):A44.
24. Pratley RE, Dengel D, Hagberg J, Roadarmel KR, Goldberg AP. Dose-response relationship between insulin and plasma norepinephrine appearance in man. *Diabetes*. 1993 42(Suppl 1):A245.
25. Rubin MA, Miller JP, Smith AR, Smith ME, Patterson KY, Pratley RE, Hurley BF, Veillon C, Anderson RA, Moser-Veillon PA. Effects of strength training on glucose chromium metabolism in males 53-63 years of age. *FASEB J*. 1993 7:A62.
26. Dengel DR, Pratley RE, Goldberg AP, Hagberg JM. Effect of aerobic exercise and weight loss on "syndrome X." *Med Sci Sports & Exercise*. 1994 May;26(5):S135.
27. Smith AJ, Pratley RE, Goldberg AP, et al. Increased insulin sensitivity with resistive training (RT) is accentuated by weight loss in postmenopausal women. *Clin Res*. 1994 42(2): A216.
28. Dengel DR, Pratley RE, Hagberg JM, Goldberg AP. Aerobic exercise and weight loss ameliorate coronary artery disease risk factors associated with the insulin resistance syndrome (syndrome X). *Clin Res*. 1994 42:A216.
29. Pratley RE, Dengel DR, Hagberg JM, Goldberg AP. Insulin resistance, hyperinsulinemia, and increased sympathetic nervous system activity associated with hypertension improve with diet and exercise. *Diabetes*. 1994 43(Suppl 1):A46.
30. Smith AJ, Pratley RE, Engelhardt SM, Goldberg AP, Elahi D. Resistive training and weight loss is an effective modality to improve glucose metabolism in post-menopausal women. *Int J Obes*. 1995 18(Suppl 2):S141.
31. Monroe MB, Pratley R, Skinner JS. Body composition of individuals with spinal cord injury as measured by dual x-ray absorptiometry (DEXA) and standard anthropometric techniques. *Med Sci Sports and Exercise*. 1994 26(Suppl 5):120.
32. Dengel DR, Pratley RE, Hagberg JM, Goldberg AP. Differentiating the effects of exercise and weight loss on glucose metabolism. *Med Sci*. 1995 27(Suppl 5):S49.
33. Ossowski VM, Pratley RE, Thompson DB. Retention of defects in insulin action in vivo in cultured human skeletal muscle cells (HSMC). *Diabetes*. 1995 44(Suppl 1):A165.
34. Pratley RE, Tataranni PA. Quantification of the effect of weight gain on insulin action in Pima Indians. *Diabetes*. 1995 44(Suppl 1):A153.
35. Pratley RE, Rogus EM, Muller DC, Goldberg AP. Aerobic exercise decreases central body fat, hyperinsulinemia and insulin resistance in sedentary older men. *J Investigative Med*. 1995.
36. Nagi DK, Tracy RP, Pratley R. Effects of endogenous and exogenous hyperinsulinemia on plasminogen-activator inhibitor (PAI-1) in Pima Indians. *Diabetologia*. 1995 38(Suppl 1):A139.
37. Pratley RE, Tataranni PA, Bogardus C, Ravussin E. Abdominal obesity does not predict the development of insulin resistance in Pima Indians. *Obes Res*. 1995 3(Suppl 3):348S.
38. Tataranni PA, Pratley R, Bogardus C, Ravussin E. Effect of body weight gain on acute insulin response in non-diabetic Pima Indians. *Obes Res*. 1995 3(Suppl 3):400S.
39. Ravussin E, Jackman MR, Karmikel R, Norman RA, Rowe M, Pratley R, Milner M, Willis WT. Effect of a polymorphism in the ND1 mitochondrial gene on mitochondrial function. *Obes Res*. 1995 3(Suppl 3):390S. PMID: 18239645.
40. Pratley RE, Milner MR, Chen KW, Elam E. Increased visceral fat associated with insulin resistance and hyperinsulinemia in Pima Indians. *Diabetes*. 1996 45(Suppl 2):1204.
41. Youngren JF, Goldfine ID, Pratley RE. Insulin resistance is related to defects in insulin receptor kinase activation in Pima Indians. *Diabetes*. 1996 45(Suppl 2):1139.

42. Mena A, Milner M, Pratley RE. Relation of androgen levels to obesity and insulin action in Pima Indians. *Endo*. 1996 96.
43. Levy-Marchal C, Pettitt DJ, Pratley RE, Bogardus C. Insulin resistance without insulin secretion defect is associated with low birth weight in young adults at risk for NIDDM. *Diabetologia*. 1996 39(Suppl 1):190.
44. Pratley RE, Tataranni PA, Snitker S, Bogardus C, Ravussin E. Abdominal obesity is associated with higher plasma leptin concentrations. *Obes Res*. 1996 4(Suppl 1):25S.
45. Pratley RE, Nicolson M, Bogardus C, Ravussin E. Plasma leptin responses to feeding and fasting. *Obes Res*. 1996 4(Suppl 1):42S.
46. Ravussin E, Pratley RE, Maffei M, Wang H, Friedman JM, Bennett PH, Bogardus C. Weight gain in Pima Indians is associated with low plasma leptin concentrations. *Obes Res*. 1996 4(Suppl 1):13S.
47. Tataranni PA, Maffei M, Pratley R, Ravussin E. The orexigenic effect of glucocorticoids is independent of changes in plasma leptin concentrations. *Obes Res*. 1996 4(Suppl 1):39S.
48. Paulik MA, Hamacher LL, Yarnall DP, Jennermann C, Maianu L, Pratley RE, Garvey WT, Burns DK, Lenhard JM. Identification of Rad's effector-binding domain, intracellular-localization and analysis of expression in Pima Indians. *Mol Biol Cell*. 1996 7(Suppl S):3060.
49. Pratley RE, Thompson DB, Prochazka MP, et al. A genome scan for linkage to quantitative traits predicting NIDDM in Pima Indians. *Diabetes*. 1997 46(Suppl 1):653.
50. Tataranni PA, Pratley RE. Higher total body bone mineral density in middle age Pimas vs. Caucasians is not related to hyperinsulinemia. *Diabetes*. 1997 46(Suppl 1):967.
51. Mott DM, Pratley R, Bogardus C. Degree of obesity in non-diabetic Pima Indian is associated with insulin stimulated glucose incorporation into lipid in cultured myoblasts. *Diabetes*. 1997 46(Suppl 1):343.
52. Sell SM, Ren KM, Milner MR, Pratley RE. Insulin acutely increases leptin mRNA expression in vivo in humans. *Diabetes*. 1997 46(Suppl 1):1351.
53. Pratley RE, Thompson DB, Prochazka M, Baier L, Mott D, et al. Genome scan for linkage to pre-diabetic traits in Pima Indians. *Diabetologia*. 1997 40(Suppl 1):615.
54. Tataranni PA, Nicolson M, Snitker S, Pratley RE, Ravussin E. Twenty-four hour respiratory quotient is negatively related to plasma leptin concentration in Pima males. *Diabetologia*. 1997 40(Suppl 1):1046.
55. Bekele G, Tataranni PA, Wilson CA, Pratley RE. Early morning decreases in plasma leptin concentration: Contributions of circadian rhythm and food intake. *Endo*. 1997 97:119.
56. Silver K, Walston J, Yang Y, Rabin N, Pratley R, Bogardus C, Shuldiner AR. Molecular scanning of the beta-3-adrenergic receptor in Pima Indians. *Genet Diabetes*, Ystad, Sweden, July 1997.
57. Pratley RE, Tataranni PA, Snitker S, Salbe A, Bekele G, Ravussin E, Mott DM, Bogardus C. Higher plasma leptin concentrations are associated with insulin resistance independently of obesity in Pima Indians. *Obes Res*. 1997 5(Suppl 1):31S.
58. Pratley RE, Thompson DB, Tataranni PA, Snitker S, Bogardus C, Ravussin E. A Gln/Arg polymorphism at amino acid 223 of the leptin receptor is associated with lower CSF leptin concentrations. *Obes Res*. 1997 5(Suppl 1):30S.
59. Wilson CA, Nelson RG, Nicolson M, Pratley RE. Diabetic nephropathy alters renal leptin metabolism but not plasma leptin concentrations. *Obes Res*. 1997 5(Suppl 1):86S.
60. Permana PA, McAllister L, Hayashibara K, Brown PO, Pratley RE, Bogardus C. Differential gene expression in skeletal muscle of non-diabetic insulin resistant and insulin sensitive Pima Indians. *Diabetes*. 1998 47(Suppl 1):A76.
61. Gautier JF, Milner MR, Ravussin E, Pratley RE. Visceral adiposity does not explain hyperinsulinemia in Pima Indians. *Diabetes*. 1998 47(Suppl 1):A299.
62. Mott DM, Pratley RE, Bogardus C. Glucose and lipid metabolism in cultured muscle from biopsies obtained before and after a 3 day fast. *Diabetes*. 1998 47(Suppl 1):A419.
63. Pratley RE, Mott DM, Milner M, Ravussin E, Knowler WC. The acute insulin response to glucose is lower in glucose tolerant offspring of Pima Indians with early onset diabetes. *Diabetes*. 1998 47(Suppl 1):A79.
64. Wilson C, Pratley R. 24-hour urinary albumin excretion is related to insulin action and is a familial trait in non-diabetic Pima Indians. *Diabetes*. 1998 47(Suppl 1):A128.

65. Pratley RE, Gautier J-F, Milner MR, Ravussin E. Effect of abdominal fat on insulin action and energy metabolism in Pima Indians. *Int J Obes*. 1998 22(Suppl 3):S217.
66. Gautier JF, Tataranni PA, Chen K, Uecker A, Salbe AD, Pratley RE, Lawson M, Ravussin E, Reiman EM. Neuroanatomical correlates of taste in fasted humans using positron emission tomography. *Int J Obes*. 1998 22(Suppl 3):S34.
67. Tataranni PA, Chen K, Uecker A, Salbe AD, Pratley RE, Lawson M, Reiman EM, Ravussin E. Identification of regions of the human brain involved in hunger and satiation using positron emission tomography. *Int J Obes*. 1998 22(Suppl 3):S34.
68. Norman RA, Tataranni PA, Pratley R, Thompson DB, Prochazka M, Baier L, Sakul H, Foroud T, Garvey WT, Burns D, Knowler WC, Bennett PH, Hanson RL, Bogardus C, Ravussin E. A genome-wide scan for obesity susceptibility genes in Pima Indians. *Int J Obes*. 1998 22(Suppl 3):S21.
69. Pratley RE, Thompson DB, Prochazka M, Baier L, Bogardus C, Pima Diabetes Genes Group. A genomic scan for linkage to traits predicting type 2 diabetes in Pima Indians. 10th Annual Indian Health Service Research Conference, 1998.
70. Weyer C, Bogardus C, Mott DM, Pratley RE. A longitudinal study on insulin secretory dysfunction and insulin resistance during the development of type 2 diabetes. *Diabetes*. 1999 48(Suppl 1):A27.
71. Weyer C, Pratley RE. A comparison of the metabolic characteristics of individuals with "impaired fasting glucose" and "impaired glucose tolerance." *Diabetes*. 1999 48(Suppl 1):A28.
72. Wilson CA, Weyer C, Knowler WC, Pratley RE. Acute insulin secretion is impaired in adult offspring of diabetic pregnancies. *Diabetes*. 1999 48(Suppl 1):A300.
73. Hanson KL, Weyer C, Pratley RE. A comparison of the effects of weight loss and weight gain on insulin action. *Diabetes*. 1999 48(Suppl 1):A225.
74. Weyer C, Bogardus C, Pratley RE. Metabolic factors contributing to the increase in resting metabolic rate (RMR) during the development of type 2 diabetes in Pima Indians. *FASEB J*. 1999 13(4) (Suppl S):A54.
75. Gautier JF, Chen K, Salbe AD, Bandy D, Pratley RE, Ravussin E, Reiman EM, Tataranni PA. Satiation elicits different responses in the brain of obese and lean men. *Obes Res*. 1999 7(Suppl 1):44S.
76. Gautier JF, Chen K, Salbe AD, Bandy D, Pratley RE, Ravussin E, Reiman EM, Tataranni PA. Effect of satiation on human brain activity: a comparison between obese and lean women. *Obes Res*. 1999 7(Suppl 1):81S.
77. Weyer C, Pratley RE, Bogardus C, Ravussin E, Tataranni PA. A longitudinal study of the changes in 24-h energy expenditure and substrate oxidation associated with long-term weight changes. *Obes Res*. 1999 7(Suppl 1):20S.
78. Gautier JF, Wilson C, Weyer C, Mott D, Knowler WC, Polonsky K, Bogardus C, Pratley RE. Insulin secretion in glucose tolerant offspring correlates with age of onset of type 2 diabetes in the parents. *Diabetologia*. 1999 42(Suppl 1):A78.
79. Weyer C, Pratley R. Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians. *Obes Res*. 1999 7(Suppl 1):29S.
80. Pratley RE, Baier L, Salbe A, Bogardus C. A polymorphism in the intestinal fatty acid binding protein affects non-esterified fatty acid responses to dietary fat in humans: a paradigm for clinical research in the genome era. Association for Patient Oriented Research; 1999 May 1; Atlantic City, NJ.
81. Bogardus C, Baier L, Pratley R, Prochazka M, Hanson R. The etiology of type 2 diabetes mellitus in Pima Indians. Symposium on Common Disease-Genetic and Pathogenetic Aspects of Multifactorial Diseases, 1999.
82. Weyer C, Bogardus C, Tataranni PA, Pratley RE. Natural history of insulin resistance and insulin secretory dysfunction in the development of type 2 diabetes mellitus and their improvement with weight loss: results from a longitudinal study in Pima Indians. American Diabetes Association Conference on American Indians, 1999.
83. Weyer C, Pratley R. Lower fasting and postprandial concentrations of acylation stimulation protein (ASP) in obese Pima Indians compared to Caucasians. IBC Symposium on Obesity and Insulin Resistance, 1999.
84. Beamer BA, Yen C-J, Kao WH, Nicklas B, Dennis K, Andersen RE, Cheskin LJ, Roth J, Brancati F, Pratley R, Shuldiner AR. PRO12ALA PPAR γ 2: A common genetic variant associated with increased

- insulin sensitivity and propensity for weight regain after weight loss. American Diabetes Association 2nd Research Symposium on the Genetics of Diabetes, 1999.
85. Bogardus C, Baier L, Pratley R, Prochazka M, Hanson R. The etiology of type 2 diabetes mellitus in Pima Indians. Keystone Symposia Syllabus Diabetes Mellitus: Molecular Mechanisms, Genetics and Prospects for New Therapy, Taos, NM, Feb. 16-22, 2000, p124.
 86. Pratley R, Weyer C, Hanson R, Tataranni PA, Shuldiner A, Bogardus C. Fasting hyperinsulin-emia predicts diabetes independent of insulin resistance and is associated with a Pro12Ala polymorphism in *PPAR- γ* . Keystone Symposia Syllabus Diabetes Mellitus: Molecular Mechanisms, Genetics and Prospects for New Therapy, Taos, NM, Feb. 16-22, 2000, p 57.
 87. Pratley R, Weyer C. A defect in insulin secretion may predispose individuals with low birth weight to type 2 diabetes. *Diabetes*. 2000 49(Suppl 1):A288.
 88. Baier L, Permana P, Yang X, Pratley R, Shen G-Q, Cox NJ, Horikawa Y, Oda N, Knowler W, Bogardus C. A Calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. *Diabetes*. 2000 49(Suppl 1):A201.
 89. Weyer C, Hanson R, Tataranni PA, Bogardus C, Pratley RE. Fasting hyperinsulinemia predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of basal insulin hypersecretion. *Diabetes*. 2000 49(Suppl 1):A25-A26.
 90. Weyer C, Pratley R. Insulin action and insulinemia are closely related to the fasting plasma concentration of complement C3, but not of ASP. *Diabetes*. 2000 49(Suppl 1):A248.
 91. Hanson K, Pratley R. Interleukin-6 is associated with insulin resistance independently of obesity. *Diabetes*. 2000 49(Suppl 1):A297-A298.
 92. Wilson CA, Nelson RG, Pratley RE. Offspring of parents with diabetic nephropathy have a defect in insulin action. *Diabetes*. 2000 49(Suppl 1):A305.
 93. Weyer C, Pratley RE, Tataranni PA. The effect of birth weight on 24-h energy metabolism later in life. *Int J Obes*. 2000 24(Suppl 1):S29.
 94. Weyer C, Pratley RE, Snitker S, Ravussin E, Tataranni PA. Role of insulinemia and sympathetic nervous system activity in the link between obesity and blood pressure: a study in non-diabetic, normotensive Caucasians and Pima Indians. *Int J Obes*. 2000 24(Suppl 1):S66.
 95. DelParigi A, Gautier JF, Chen K, Salbe AD, Pratley RE, Reiman EM, Tataranni PA. Sex differences in brain response to hunger and satiation in humans. *Int J Obes*. 2000 24(Suppl 1):S122.
 96. Weyer C, Tataranni PA, Bogardus C, Pratley RE. Insulin resistance and low early phase insulin secretion predict the progression from impaired glucose tolerance (IGT) to diabetes in Pima Indians. *Diabetologia*. 2000 43(Suppl 1):A72.
 97. Yang X, Pratley RE, Permana PA. Use of oligonucleotide microarrays to identify novel candidate genes for insulin resistance in non-diabetic Pima Indians. American Diabetes Association Scientific Sessions, 2000.
 98. Vozarova B, Weyer C, Bogardus C, Pratley RE, Tataranni PA. Increased oral temperature is associated with insulin resistance in Pima Indians. American Diabetes Association Research Symposium on the Impact of Ethnicity and Race on Diabetes, Dana Point, CA, November 30-December 2, 2000.
 99. Namata G, Weyer C, Pratley R. Acute insulin secretory responses to glucose are higher in African-Americans with normal glucose tolerance than in Caucasians. American Diabetes Association Research Symposium on the Impact of Ethnicity and Race on Diabetes, Dana Point, CA, November 30-December 2, 2000.
 100. Pratley RE, Yang X, Adams SH, Yu XX, Pan G, Permana P. Skeletal muscle UCP5/ BMCP1 mRNA levels are related to plasma insulin, resting metabolic rate and lipid oxidation rate in humans. *Obes Res*. 2000 8(Suppl 1):31S.
 101. Namata G, Weyer C, Pratley R. Acute insulin secretory responses to glucose are higher in African-Americans with normal glucose tolerance than in Caucasians. *Obes Res*. 2000 8(Suppl 1): 123S.
 102. Salbe AD, Tataranni PA, DelParigi A, Pratley RE. Hedonic responses to fat-sugar mixtures in Pima Indian and Caucasian adults. *Obes Res*. 2000 8(Suppl 1):24S.
 103. Weyer C, Vozarova B, Gautier J-F, Pratley RE, Cizza G, Chrousos G, Ravussin E, Tataranni PA. Effect of overnight partial chemical adrenalectomy and subsequent hydrocortisone infusion on muscle

- sympathetic nerve activity and resting metabolic rate in Caucasians and Pima Indians. *Obes Res.* 2000 8(Suppl 1):30S.
104. Namata G, Weyer C, Pratley R. Acute insulin secretory responses to glucose are higher in African-Americans with normal glucose tolerance than in Caucasians. 2000 NIH Research Festival, Bethesda, MD, October 10-13, 2000.
 105. Goldberg A, Rogus E, Pratley RE, Busby-Whitehead J, Muller D, Hagberg J. Metabolic adaptations to long-term exercise: master athletes. *J Aging Phys Activ.* 2000 8:253-254.
 106. Lee YH, Pratley RE, Luczy-Bachman G, Tokraks S, Bogardus C, Permana PA. Identification of differentially expressed genes in skeletal muscle of non-diabetic insulin sensitive and insulin resistant Pima Indians by differential display RT-PCR. *Diabetes.* 2001 50(Suppl 2):A246.
 107. Mott DM, Pratley RE. Studies on mechanism for free fatty acid inhibition of glycogen synthase activity in human myoblasts. *Diabetes.* 2001 50(Suppl 2):A277.
 108. Namata G, Gautier JF, Hanson R, Pratley RE, Bogardus C, Tataranni PA. In utero exposure to diabetes mellitus impairs insulin secretion in adult Pima Indians. *Diabetes.* 2001 50(Suppl 2):A385.
 109. Vozarova B, Weyer C, Wilson C, Pratley RE, Tataranni PA. Elevated white blood cell count predicts type 2 diabetes in Pima Indians. *Diabetes.* 2001 50(Suppl 2):A536.
 110. Weyer C, Yudkin JS, Stehouwer CDA, Schalkwijk CG, Pratley RE, Tataranni PA. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. *Diabetes.* 2001 50(Suppl 2):A314.
 111. Haffner S, Hotman R, Califf R, McMurray J, Pecher E, Pratley R. Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial. *Diabetologia.* 2002 45(Suppl 2):319.
 112. Vozarova B, Stefan N, Funahashi T, Matsuzawa Y, Lindsay RS, Weyer C, Youngren JF, Havel P, Pratley RE, Bogardus C, Tataranni PA. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans. *Diabetes.* 2002 51(Suppl 2):1462.
 113. Vozarova B, Stefan N, Lindsay RS, Saremi A, Pratley RE, Bogardus C, Tataranni PA. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. *Diabetes.* 2002 51(Suppl 1):1426.
 114. Sobngwi E, Boudou P, Mauvais-Jarvis F, LeBlanc H, Velho G, Vexiau P, Porcher R, Pratley R, Tataranni PA, Calvo F, Gautier JF. Predisposition to type 2 diabetes in offspring of type 1 diabetic mothers is associated with reduced insulin secretion and a low parasympathetic drive to the pancreas. *Diabetes.* 2003 52(Suppl):A32-A33.
 115. Stefan N, Weyer C, Levy-Marchal C, Stumvoll M, Knowler W, Tataranni P, Bogardus C, Pratley R. Endogenous glucose production, insulin sensitivity and insulin secretion in normal glucose tolerant Pima Indians with low birth weight. *Diabetes.* 2003 52(Suppl 1):A339.
 116. Mari A, Gastaldelli A, Foley J, Pratley R, Ferrannini E. Effect of nateglinide on beta-cell function in patients with mild Type 2 diabetes: a model analysis. *Diabetologia.* 2003 46(Suppl):480.
 117. Holman R, Fonseca V, Deedwania P, Haffner S, Pratley R. Frequency of abnormal glucose tolerance and the metabolic syndrome in people at increased cardiovascular disease risk screened for the NAVIGATOR trial. *Eur Heart J.* 2003 24(Suppl S):671.
 118. Deedwania PC, Krum H, Horton E, Pecher E, Khemlani LS, Pratley RE. NAVIGATOR trial shows a relationship between cardiovascular disease risk factors and abnormal glycaemic status. Poster: 1414. Presented at 18th International Diabetes Federation Congress, Paris, 24-29 August, 2003.
 119. Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM). *Diabetes.* 2004 53(Suppl 2):A83 (Abstract 355-OR).
 120. Pratley RE, Gomis R, Standl E, Schweizer A, Mills D, Ahren B. Long-term efficacy of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes inadequately treated with metformin. *Diabetologia.* 2004 47(Suppl 1):A69 (Abstract 357).
 121. DelParigi A, Schonberger SJ, DeCourten B, Pratley R, Cooper GJ, Tataranni PA. Proteome analysis of cerebrospinal fluid in an obesity prone population. *Obesity Research.* 2004.

122. Lee YH, Watson A, Bond J, Permana P, Pratley R. Gender-BMI interaction and gene regulation in abdominal subcutaneous adipocytes of non-diabetic Pima Indians. *Obesity Research*. 2005 13(Suppl S):A109.
123. Foley JE, Ligueros-Saylan M, Watson CA, Lee YH, Dunning BE, Pratley RE, D'Alessio DA. Differential effects of vildagliptin on islet function in patients with type 2 diabetes receiving no additional agent or concomitant metformin. *Diabetologia*. 2006 49(Suppl 1):397-8. (Abstract PS-46).
124. Lee YH, Trost S, Tharp WG, Nair S, Permana PA, Pratley RE. Overexpression of endocannabinoid receptor 1 (CB 1) in obese individuals. *Diabetes*. 2006 55(Suppl 1):A313 (Abstract 1340-P).
125. D'Alessio DA, Watson CE, Yan-ling HE, Ligueros-Saylan M, Pratley R, et al. Restoration of an acute insulin response to glucose (AIRg) in drug-naïve patients with type 2 diabetes by 3-month treatment with vildagliptin. *Diabetes*. 2006 55(Supplement 1):A108 (Abstract 454-P).
126. Tharp WG, Lee YH, Trost S, Gokin AP, Habibovic A, Pratley RE. The endocannabinoid receptor CB1 is upregulated in visceral adipose tissue but is not affected by hyperglycemia in obese Zucker rats. *Diabetes*. 2006 55(Supplement 1):A318 (Abstract 1362-P).
127. Lee YH, Tharp W, Peshavaria M, Nair S, Permana P, Pratley RE. Overexpression of amyloid precursor peptide (APP) in adipose tissue of obese individuals. NAASO 2006 Annual Scientific Meeting, Boston MA, 2006.
128. Tharp W, Lee YH, Peshavaria M, Lausier J, Pratley RE. CB1 is expressed on somatostatin producing δ -cells in pancreatic islets. NAASO 2006 Annual Scientific Meeting, Boston MA, 2006.
129. Tharp W, Lee YH, Gokin A, Habibovic A, Leahy J, Pratley RE. Hyperglycemia is associated with elevated markers of inflammation in epididymal adipose tissue in obese Zucker rats. NAASO 2006 Annual Scientific Meeting, Boston MA, 2006.
130. Foley JE, Ligueros-Saylan M, Watson C, He Y-L, Dunning BE, Pratley RE, D'Alessio DA. Differential effects of vildagliptin on islet function in patients with type 2 diabetes receiving no additional agent or concomitant metformin. *Diabetologia*. 2006 Sep:49(Suppl 1):397-8.
131. Hurowitz L, Pratley R, Wasserman R, Cote E, Coburn S, Forlano L. Statewide Promotion of Healthier Weight – Primary Care Initiatives. Public Health Systems Research Interest Group Meeting, Orlando FL, 2007.
132. Lee YH, Martin JM, Singaram V, Spaulding L, Dixon AE, Pratley RE. Decreased expression of amyloid precursor protein in human adipose tissue with weight loss. *Diabetes*. 2007 56(Suppl 1):A356 (Abstract 1386-P).
133. Jamal SR, Hardison R, Pratley RE, Sobel BE. Associations of concentrations of PAI-1 antigen with obesity and physical inactivity in participants with type 2 diabetes and established coronary disease in the BARI2D trial. *Diabetes*. 2007 56(Suppl 1):A15 (Abstract 0057-OR).
134. Pratley RE, Schweizer A, Couturier A, Dejager S. Achieving glycemic goals with Vildagliptin. *Diabetes*. 2007 56(Suppl 1):A134 (Abstract 0504-P).
135. Rosenstock J, Pi-Sunyer FX, Pratley RE, Couturier A, Schweizer A, Dejager S. Robust efficacy of Vildagliptin in drug-naïve patients: pooled analysis of 5 monotherapy studies. *Diabetes*. 2007 56(Suppl 1):A135 (Abstract 0506-P).
136. Pratley RE, Rosenstock J, Pi-Sunyer FX, Couturier A, Schweizer A, Dejager S. Benefit/risk assessment of Vildagliptin in the elderly: pooled analysis of 5 monotherapy studies. *Diabetes*. 2007 56(Suppl 1):A135 (Abstract 0507-P).
137. Pratley RE, Hardison R, Tilton L, Sobel B. Effects of diabetes medications on fibrinolytic activity: the BARI2D test. *Diabetes*. 2007 56(Suppl 1):A169 (Abstract 0636-P).
138. Singaram V, Martin JM, Dixon AE, Ades PA, Savage PD, Spaulding L, Pratley RE, Lee YH. Overexpression of amyloid precursor protein in adipose tissue of obese diabetic vs obese non-diabetic individuals. *Diabetes*. 2007 56(Suppl 1):A363 (Abstract 1413-P).
139. Lee Y, Dixon A, Tharp W, Maple R, Wachtel D, Spaulding L, Pratley R. Increased adipose tissue in PAI-1 gene expression in obesity-associated asthma. *Obesity*. 2007 Oct:591-P.
140. Pratley RE, Schweizer A, Couturier A, Dejager S. Achieving Glycemic Goals with Vildagliptin. *Diabetologia*. 2007 Oct. (Abstract 0504-P).
141. Pratley RE, Rosenstock J, Pi-Sunyer FX, Couturier A, Schweizer A, Dejager S. Benefit/risk assessment of vildagliptin in the elderly: pooled analysis of 5 monotherapy studies. *Diabetologia*. 2007 Oct:0507-P.

142. Dejager S, Schweizer A, Couturier A, Pratley RE. Achievement of glycaemic targets with vildagliptin. European Association for the Study of Diabetes. European Association for the Study of Diabetes Annual Meeting. Amsterdam 2007 (Abstract 885).
143. Rosenstock J, Pi-Sunyer FX, Couturier A, Schweizer A, Dejager S. Efficacy and safety of vildagliptin in the elderly: pooled analysis of 5 monotherapy studies. European Association for the Study of Diabetes Annual Meeting. Amsterdam 2007 (Abstract 887).
144. Pratley R, Reusch J, Fleck P, Wilson C, Mekki Q. Alogliptin added to pioglitazone therapy improves glycaemic control in patients with type 2 diabetes without increasing weight gain or hypoglycaemia. European Association for the Study of Diabetes. European Association for the Study of Diabetes Annual Meeting. Italy, 2008 (Abstract 860).
145. Fleck P, Mekki Q, Kipnes M, Wilson C, Pratley R. Efficacy and safety of alogliptin and glyburide combination therapy in patients with type 2 diabetes. European Association for the Study of Diabetes. European Association for the Study of Diabetes Annual Meeting. Italy, 2008 (Abstract 76).
146. Braceras R, Blonde L, Banerji M., Dagogo-Jack S, Pratley R, Marcellari A, Purkayastha D, Baron M. Vildagliptin is as effective as TZDs in metformin failures: results of GALIANT - a primary care diabetes study. European Association for the Study of Diabetes Annual Meeting. Italy, 2008 (Abstract 914).
147. Pratley R, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin Use in Elderly People: A Pooled Analysis from Phase 2 and 3 Studies. European Association for the Study of Diabetes. European Association for the Study of Diabetes Annual Meeting. Austria, 2009 (Abstract 765).
148. Burant C, Fleck P., Wilson C., Mekki Q., Pratley R, DeFronzo R. Effect of alogliptin combined with pioglitazone on beta cell function and insulin resistance in metformin-treated patients with type 2 diabetes. European Association for the Study of Diabetes Annual Meeting. Austria, 2009 (Abstract 800).
149. DeFronzo R, Burant C, Fleck P, Wilson C, Mekki Q, Pratley R. Effect of alogliptin combined with pioglitazone on glycaemic control in metformin-treated patients with type 2 diabetes. European Association for the Study of Diabetes Annual Meeting. Austria, 2009 (Abstract 752).
150. Holst JJ, Nauck M, Brett J, Falahati A, Pratley R. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomized clinical trials. European Association for the Study of Diabetes Annual Meeting. Austria, 2009 (Abstract 736).
151. Dixon AE, Pratley RE, Spaulding L, Kaminsky DA, Whittaker LA, Forgione PM, Bourassa LM, Raymond DM, Wachtel D, Irvin CG. Pathophysiological Changes in Asthma Induced by Weight Loss. *Proc Am Thorac Soc*. 2009 May 1;6(3):328. (Abstract)
152. Sideleva O, Tharp WG, Jaworski DM and Pratley RE. TIMP-2 Deficiency: A New Murine Model of Obesity and T2DM. *Diabetes*. 2010 70th Scientific Session of the American Diabetes Association; 2010 Jun 25-29; Orlando, FL. (Abstract 468-PP).
153. White WB, Gorelick PB, Fleck P, Smith N, Wilson C, and Pratley RE. Cardiovascular Events in Patients Receiving Alogliptin: A Pooled Analysis of Randomized Clinical Trials. 70th Scientific Session of the American Diabetes Association; 2010 Jun 25-29; Orlando, FL. (Abstract 391-PP).
154. Gilbert MP, Bunn JY, Maple R, Christian R and Pratley RE. The Effect of Sitagliptin on Markers of Bone Metabolism in Patients with Type 2 Diabetes Mellitus. 70th Scientific Session of the American Diabetes Association; 2010 Jun 25-29; Orlando, FL. (Abstract 2183-PO).
155. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen A, Hartvig H and Davies M. Liraglutide Treatment for 1 Year Offers Sustained and More Effective Glycemic Control and Weight Reduction Compared with Sitagliptin, Both in Combination with Metformin, in Patients with Type 2 *Diabetes*. 70th Scientific Session of the American Diabetes Association; 2010 Jun 25-29; Orlando, FL. (Abstract 16-LB).
156. Davies M, Pratley R, Montanya E, Thomsen A, Falahati A and Sesti G. Liraglutide Reduces A1c to a Greater Extent Than Sitagliptin Regardless of Baseline A1c Levels. 70th Scientific Session of the American Diabetes Association; 2010 Jun 25-29; Orlando, FL. (Abstract 57-OR).
157. Garber A, Thomsen A, Falahati A and Pratley RE. Liraglutide Promoted More Weight Loss with Improved Glycemic Control Than Sitagliptin. 70th Scientific Session of the American Diabetes Association; 2010 Jun 25-29; Orlando, FL. (Abstract 697-P).
158. Pratley R, Gilbert M, Marre M, Brett J, Chang CT, Holst J, Diamant M and Garber A. Bone Mineral Density Is Not Affected by Liraglutide in Patients with Type 2 Diabetes Already at Risk of Fracture. 70th

- Scientific Session of the American Diabetes Association; 2010 Jun 25-29; Orlando, FL. (Abstract 1634-P).
159. Montanya E, Cuddihy R, Pratley R, Hammer M, Bloch-Thomsen A, Davies M. Liraglutide leads to greater improvement in treatment satisfaction than sitagliptin, each combined with metformin, in patients with type 2 diabetes. European Association for the Study of Diabetes Annual Meeting 2010.
 160. Pratley R, Davies M, Hammer M, Bloch-Thomsen A, Cuddihy R. Liraglutide Improves Treatment Satisfaction Compared to Sitagliptin, in Type 2 Diabetes Canadian Diabetes Association Annual Meeting 2010:91-P.
 161. Garber A, Thomsen AB, Falahati A, Pratley R. Liraglutide treatment provides greater weight loss with improved glycaemic control than sitagliptin, both combined with metformin. *Diabetologia*. 2010 53(Suppl. 1):S332. (Abstract 834).
 162. Montanya E, Cuddihy R, Pratley R, Hammer M, Thomsen AB, Davies M. Treatment satisfaction in patients with type 2 diabetes is significantly improved with liraglutide, the once-daily GLP-1 analogue versus sitagliptin, both combined with metformin. *Diabetologia* 2010 53(Suppl. 1):S331 European Association for the Study of Diabetes Annual Meeting 2010. (Abstract 832).
 163. Zinman B, Davies M, Pratley R, Hammer M, Thomsen A, McGirr M, Cuddihy R. Liraglutide improves treatment satisfaction in subjects with type 2 diabetes compared to sitagliptin, each as add-on to metformin. Presented at the Australian Diabetes Society Annual Scientific Meeting, September 2010. (Abstract 381).
 164. Zinman B, Davies M, Pratley R, Montanya E, Thomsen AB, McGirr M, Sesti G. Liraglutide reduces A1c to a greater extent than sitagliptin regardless of baseline A1c levels. Presented at the Australian Diabetes Society Annual Scientific Meeting, 1–3 September 2010 Sydney, Australia. (Abstract 380).
 165. Zinman B, Garber A, Thomsen AB, Falahati A, Gough S, Daja M, Pratley R. Liraglutide promoted more weight loss with improved glycemic control than sitagliptin. Presented at the Australian Diabetes Society Annual Scientific Meeting, 1–3 September 2010, Sydney, Australia: Abstract 383.
 166. Pratley R, Davies M, Hammer M, Thomsen AB, Cuddihy R. Liraglutide Improves Treatment Satisfaction Compared to Sitagliptin, in Type 2 Diabetes. Poster, Presented at the 13th Annual CDA/CSEM Congress, Edmonton, Canada, October 2010.
 167. Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M. Liraglutide Treatment for One Year Offers Sustained and More Effective Glycemic Control and Weight Reduction than Sitagliptin, Both in Combination With Metformin. Oral, Presented at the 13th Annual CDA/CSEM Congress, Edmonton, Canada, October 2010.
 168. Davies M, Nauck MA, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Sondergaard AE, Pratley R. Better glycaemic control and weight reduction with liraglutide, a once-daily human GLP-1 analogue, compared with sitagliptin, a DPP-4 inhibitor, both in combination with metformin in Type 2 diabetes. *Diabet Med*. 2010; 27 (Suppl. 1):Oral A10 and Poster 141, DUK, 2010.
 169. Davies M, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Pratley R. Liraglutide treatment for 1 year offers more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin and type 2 diabetes. *J Diabetes*. 2011 3(Suppl. 1):15 (Oral). ICPDMS, 2011.
 170. Davies M, Pratley R, Montanya E, Thomsen AB, Falahati A, Sesti G. Liraglutide reduces HbA1c to a greater extent than sitagliptin regardless of baseline HbA1c. *J Diabetes*. 2011; 3 (Suppl. 1):185 (Poster), ICPDMS, 2011. (Abstract 57-OR).
 171. Henry R, Buse J, Sesti G, Davies M, Jensen K, Brett J, Pratley R. Glycemic control achieved with liraglutide regardless of baseline HbA1c levels. AACE 2011 (Abstract 222).
 172. Bailey T, Pratley R, Buse J, Furber S, Hartvig H, Schmidt WE. Comparison of incretin-based therapies: liraglutide offers greater improvements in A1c than sitagliptin or exenatide across baseline A1c categories. *Diabetes*. 2011; 60(Suppl. 1):A599. (Abstract 2252-PO).
 173. Davies M, Pratley R, Montanya E, Brett J, Hartvig J, Sesti G. One-year liraglutide treatment reduces A1c to a greater extent than sitagliptin, both in combination with metformin, independent of baseline A1c levels. *Diabetes*. 2011; 60(Suppl. 1):A615. (Abstract 2314-PO).
 174. Montanya E, Pratley R, Nauck M, Bailey T, Garber A, Filetti S, Thomsen AB, Hammer M, Davies M. Switching from sitagliptin to liraglutide, in combination with metformin, improves treatment satisfaction in patients with type 2 diabetes. *Diabetes*. 2011; 60(Suppl. 1):A307. (Abstract 1118-P).

175. Pratley R, Grimmshave L, Xu Y, Garber A. One-year liraglutide treatment offers greater weight reduction and more improved glycemic control compared with sitagliptin, both in combination with metformin. *Diabetes*. 2011; 60(Suppl. 1):A615. (Abstract 2313-PO)
176. Pratley R, Nauck M, Bailey T, Montanya E, Filetti S, Garber A, Thomsen AB, Hartvig H, Davies M, for the 1860-LIRA-DPP-4 Study Group. Switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide further improves glycemic control and weight loss in patients with type 2 diabetes. *Diabetes*. 2011; 60(Suppl. 1):A307
177. Zinman B, Gough S, Pratley RE, Brett J, Lund N, Buse J. Effect of Liraglutide, Exenatide, and Sitagliptin on the composite outcome of glycemic control and weight loss. *Diabetes*. 2011; 60(Suppl. 1):A289. (Abstract 1055-P)
178. Davies M, Buse J, Sesti G, Pratley R, Jensen K, Brett J, Henry R. Glycaemic Control Achieved with Liraglutide Regardless of Baseline A1c Levels. Presented at the 14th Annual CDA/CSEM Congress Toronto, Canada, October 2011.
179. Davies M, Nauck M, Bailey T, Montanya E, Filetti S, Garber A, Thomsen AB, Hartvig H, Pratley R, for the 1860-LIRA-DPP-4 Study Group. Switching from the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analogue Liraglutide Further Improves Glycaemic Control and Weight Loss in Patients with Type 2 Diabetes. Presented at the 14th Annual CDA/CSEM Congress Toronto, Canada, October 2011.
180. Davies M, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Garber A, Thomsen AB, Hartvig H, Pratley R. The GLP-1 analogue liraglutide provides more effective glycaemic control and weight reduction over 1 year compared with sitagliptin, a DPP-4 inhibitor, in patients with Type 2 diabetes inadequately controlled with metformin. *Diabet Med*. 2011 28(Suppl. 1):70 (Abstract 70) DUK, 2011.
181. Bailey T, Pratley R, Buse J, Furber S, Hartvig H, Schmidt WE. Meta-analysis indicates liraglutide can reduce A1c to a greater degree than sitagliptin or exenatide, regardless of baseline A1c. IDF 21th World Congress Abstract Book. IDF: Dubai, 2011. Poster 1020.
182. Davies M, Pratley R, Montanya E, Xu Y, Hartvig H, Sesti G. Liraglutide treatment reduces A1c over 1 year to a greater extent than sitagliptin, independent of baseline A1c, both as add-on to metformin. IDF 21th World Congress Abstract Book. IDF: Dubai, 2011. Poster 1356.
183. Fonseca V, DeVries JH, Bain SC, Pratley R, Jensen T, Hartvig H, Marso SP. Liraglutide improves the profile of lipid and cardiovascular risk biomarkers from baseline. IDF 21th World Congress Abstract Book. IDF: Dubai, 2011. Poster 1355.
184. Montanya E, Pratley R, Nauck M, Bailey T, Garber A, Filetti S, Thomsen AB, Hammer M, Davies M. Improvement in overall treatment satisfaction in patients with T2D after a switch from sitagliptin to liraglutide, combined with metformin. IDF 21th World Congress Abstract Book. IDF: Dubai, 2011. Poster 1354.
185. Pratley R, Matthews DR, Garber A, Grimmshave L, Xu Y, Sesti G. Improved weight reduction and glycaemic control with the once-daily GLP-1 analogue, liraglutide, compared with sitagliptin after 1 year. IDF 21th World Congress Abstract Book. IDF: Dubai, 2011. Poster 1353.
186. Pratley R, Nauck M, Bailey T, Montanya E, Filetti S, Garber A, Thomsen AB, Furber S, Davies M. Glycaemic control and weight loss is further improved when patients with type 2 diabetes are switched from sitagliptin to liraglutide. IDF 21th World Congress Abstract Book. IDF: Dubai, 2011. Poster 1352.
187. Zinman B, Gough S, Pratley R, Donsmark M, Lund N, Buse J. Patients achieving both glycaemic control and weight loss with liraglutide, exenatide or sitagliptin. IDF 21th World Congress Abstract Book. IDF: Dubai, 2011. Poster 1357.
188. Pratley R. Incretins (DPP-4 inhibitors and GLP-1 receptor agonists). Symposium What should follow metformin? IDF: Dubai 2011. (Abstract 115).
189. Tharp WG., Sideleva O, Elahi D, Ledger C, Maple R, Pratley R. Glucose Dependent Insulinotropic Peptide (GIP) Stimulates Insulin Secretion in Patients with Well-Controlled Type 2 Diabetes Mellitus: Effects of Metformin and Gender. *Diabetes*. 2011; 60(Suppl. 1):A447. (Abstract 1644-P)
190. Sideleva O, Tharp WG, Ferro AJ, Maple RP, Pratley RE. Pioglitazone Increases Glucose Dependent Insulinotropic Receptor (GIPR) Expression in Adipocytes in Patients with Type 2 Diabetes. *Diabetes*. 2011; 60(Suppl. 1):A437. (Abstract 1604-P)
191. Tharp WG, Sideleva O, Elahi D, Ledger C, Maple R, Pratley R. Pioglitazone (PIO) Does Not Enhance Glucose-Dependent Insulinotropic Peptide (GIP) Stimulated Insulin Secretion in Subjects with Well-Controlled T2DM. *Diabetes*. 2011; 60(Suppl. 1):A444. (Abstract 1630-P).

192. Zinman B, Gough S, Pratley R, Brett J, Lund N, Buse J. Achieving glycaemic control and weight loss with incretin-based therapies: a comparison of liraglutide, exenatide, and sitagliptin. European Association for the Study of Diabetes Annual Meeting. Portugal, 2011. (Abstract 798).
193. Davies M, Pratley R, Montanya Mias E, Xu Y, Hartvig H, Sesti G. After one year of treatment, liraglutide more successfully reduces HbA1c than sitagliptin across a broad range of baseline HbA1c values, when both are combined with metformin. European Association for the Study of Diabetes Annual Meeting. Portugal, 2011. (Abstract 792).
194. Montanya Mias E, Pratley R, Nauck MA., Bailey T, Garber A, Filetti S, Thomsen AB, Hammer M, Davies M. In patients with type 2 diabetes, overall treatment satisfaction improves following a switch from sitagliptin to liraglutide treatment in combination with metformin. European Association for the Study of Diabetes Annual Meeting. Portugal, 2011. (Abstract 796).
195. Matthews DR, Sesti G, Pratley R, Grimmshave L, Xu Y, Garber A. Liraglutide achieved greater weight reduction and improved glycaemic control compared with sitagliptin following one-year treatment when both are used in combination with metformin. European Association for the Study of Diabetes Annual Meeting. Portugal, 2011. (Abstract 793).
196. Bailey T, Pratley R, Buse J, Furber S, Hartvig H, Schmidt WE. Liraglutide produces greater reductions in HbA1c levels compared with sitagliptin or exenatide across five baseline HbA1c categories. European Association for the Study of Diabetes Annual Meeting. Portugal, 2011. (Abstract 794).
197. Tharp WG, Sideleva O, Maple RL, Ferro AJ, Ledger C, Pratley R. Independent Increases in Insulin Sensitivity and Adipocyte GIP-R expression following pioglitazone (PIO) treatment in patients with Type 2 Diabetes Mellitus (T2DM). *Obesity*. 2011 Nov;19(1Suppl) (Abstract 612-P).
198. King A, Montanya E, Pratley R, Blonde L, Svendsen C, Donsmark M, Sesti G. In T2D Patients with Baseline A1C <8.0%, Liraglutide achieves A1C targets more often than Sitagliptin or Exenatide. AACE 21st Annual Scientific and Clinical Congress. Philadelphia PA, 2012. (Abstract 1328).
199. Pratley R, Wilson C, Fleck P. Alogliptin plus Metformin combination therapy vs. Alogliptin or Metformin monotherapy for Type 2 Diabetes Mellitus. *Diabetologia*. 2012. 55:[Suppl1]S1-S537-8. (Abstract 841).
200. Kyriazis GA, Mosure KR, Soundarapandian MM, Pratley RE, Tyrberg B. "Tasting" fructose with pancreatic beta-cells: modulation of insulin release by sweet taste receptor signaling and its role in metabolic diseases. BMC Proceedings 2012, 6(Suppl 3):P29.
201. Pratley R, Stewart M, Cirkel D, Ye J, Perry C, Carr MC. HARMONY 4: 52-Wk Efficacy of Albiglutide (Albi) vs. Insulin Glargine (Glar) in Patients (pts) with T2DM. *Diabetes*. 2013. 62 (suppl 1). Abstract 54-LB.
202. Kovacova Z, Pratley RE. Dysregulated Natriuretic Peptide Receptor Expression in Human Adipose Tissue in Obesity and Insulin Resistance. *Diabetes*. 2013. 62 (suppl 1). Abstract 2110-P.
203. Martin AA, Johnson SL, Ye J, Pratley RE. Treatment Satisfaction with Albiglutide and Liraglutide in Patients with Type 2 Diabetes Uncontrolled with Oral Therapy. *Diabetes*. 2013. 62 (suppl 1). Abstract 1010-P.
204. Pratley R, Stewart M, Cirkel D, Ye J, Perry C, Carr MC. HARMONY 4:52-week efficacy of albiglutide vs. insulin glargine in patients with type 2 diabetes mellitus. *Diabetologia*. 2013. 56:[Suppl 1]S360-1. (Abstract 904)
205. Pratley RE, Kang JH, Kim PK, Kwak EH, Han OP, Gee KH, Choi IY, Kwon SC, Trautmann M, Hompesch M. Significant effects of HM11260C on body weight over 20 weeks in obese subjects without diabetes: a randomised, double-blind, placebo controlled study. European Association for the Study of Diabetes Annual Meeting. Sweden, 2015. (Abstract 643).
206. Pratley R et al. Similar Glucose Control and Hypoglycemia but Reduced Glucose Variability with Glucose Dependent and Independent Therapies in Older Patients with Type 2 Diabetes Mellitus (T2DM). 76th Scientific Session of the American Diabetes Association; 2016 Jun 10-14; New Orleans, LA. (Poster 891-P).
207. Pratley R et al. Safety and efficacy of ertugliflozin plus sitagliptin versus either treatment alone in subjects with type 2 diabetes inadequately controlled with metformin: the VERTIS FACTORIAL trial. European Association for the Study of Diabetes Annual Meeting. Germany, 2016. (Poster 728).
208. Pratley R et al. Safety and Efficacy of Ertugliflozin plus Sitagliptin vs. Either Treatment Alone after 52 Weeks in Subjects with T2DM Inadequately Controlled on Metformin: VERTIS FACTORIAL Trial

Extension. 77th Scientific Session of the American Diabetes Association; 2017 Jun 9-13; San Diego, CA. (Abstract 130-OR).